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ABSTRACT: From a high-throughput screen of 42 444 known
human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was
identified to begin optimization for the treatment of human African
trypanosomiasis. Previously reported data for analogous com-
pounds against human kinases GSK-3β, CDK-2, and CDK-4 were
leveraged to try to improve the selectivity of the series, resulting in
23a which showed selectivity for T. b. brucei over these three
human enzymes. In parallel, properties known to influence the
absorption, distribution, metabolism, and excretion (ADME)
profile of the series were optimized resulting in 20g being
progressed into an efficacy study in mice. Though 20g showed
toxicity in mice, it also demonstrated CNS penetration in a PK
study and significant reduction of parasitemia in four out of the six
mice.
■ INTRODUCTION
Human African trypanosomiasis (HAT), or sleeping sickness
as it is commonly referred to, is a parasitic disease caused by
two subspecies of Trypanosoma brucei.1 Despite sharing a life
cycle and causing similar symptoms in patients, these two
subspecies progress at vastly different rates. T. b. gambiense is
more common (98% of cases), and infection takes an average
of 3 years to run its course (ending in fatality), while T. b.
rhodesiense is more virulent and infections can cause death
within weeks to months of infection.2−4 There were 1446
documented cases of HAT in 2017, with an estimated 13
million people living in areas of moderate to high risk of
infection.1,2 Fatal if left untreated, HAT has two stages; in the
first stage T. brucei resides and multiplies in the blood and
lymphatic systems. Infections often are not diagnosed due to
nondescript symptoms, commonly associated with the flu.1,3 In
the second stage, the parasite crosses the blood−brain barrier
(BBB) to infect the central nervous system (CNS), and those
infected present more readily diagnosable symptoms such as
disruptions to sleeping patterns and cognitive dysfunction and
can become comatose.1
There are currently two approved therapies for stage 1 HAT,
pentamidine for T. b. gambiense infections and suramin for T. b.
rhodesiense infections; both are ineffective against stage 2 of the
disease.2
In the past, the two principal treatments for stage 2 of the
disease were eflornithine for T. b. gambiense and melarsoprol
for T. b. rhodesiense; the mechanisms and drawbacks of each is
discussed in a thorough review by Barret et al.5 In 2009, a
nifurtimox−eflornithine combination therapy (NECT) was
approved for treatment of T. b. gambiense infections.6 NECT
requires 14 iv infusions of eflornithine (400 mg kg−1 day−1)
over 7 days as well as oral nifurtimox 3 times a day for 10
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days.1,2,7,8 Fexinidazole, a nitroaromatic compound which
recently concluded a phase II/III clinical trial for treatment of
T. b. gambiense infections, demonstrated a 91% cure rate after
10 days of treatment, compared to 97% for NECT therapies.9
This lower cure rate was deemed acceptable as fexinidazole has
a more manageable dosing regimen due to it being orally
bioavailable; thus fexinidazole was approved for distribution in
2019 by the European Medicines Agency, becoming the first
oral therapy for HAT.3,10,11 Notably, T. b. brucei cell lines
which were resistant to nifurtimox (also a nitroaromatic
compound) were found to be resistant to fexinidazole.12 This
cross-resistance could imply similar mechanisms of action,
meaning T. b. gambiense strains resistant to NECT could also
be resistant to fexinidazole.12,13 Acoziborole (SCYX-7158),
which recently had a successful phase I clinical trial could
prove to be the first, single-dose, oral therapy for HAT;
however, it is not expected to conclude phase II/III trials until
2020.14 While promising, it should be noted that treatments
for infectious diseases fail at a higher rate in the clinic than
other drug discovery programs.15 Should resistance to NECT/
fexinidazole emerge or acoziborole fail in clinical trials, there
would be few remaining treatment options for HAT.
Despite the need for treatment options, there has been little
investment from the pharmaceutical industry due, in-part, to a
lack of financial incentive, which led to the designation of HAT
as a neglected tropical disease by the World Health
Organization.16,17 With the lack of investment there has been
an increasing effort in academic settings and in industrial−
academic partnerships to aid the drug discovery process.18
Traditional drug discovery programs can be time-consuming
and costly, often starting from a high-throughput screen
(HTS) and going through target validation, hit-to-lead
optimization, and in vivo testing before advancing to clinical
trials.17 We hypothesize that employing one of a variety of drug
repurposing strategies can help to shorten the timelines
associated with this process.17
T. b. brucei expresses 176 kinases (156 which are described
as eukaryotic protein kinases). Many of these are crucial to
survival of the parasite, and several have human orthologs
which have been pursued in drug discovery.19−22 With this in
mind, we undertook a lead repurposing study against T. b.
brucei using a biased library of known human kinase
inhibitors.18 Starting from a library of 42 444 kinase inhibitors,
we identified 797 compounds that showed submicromolar
activity against T. b. brucei, as well as >100-fold selectivity over
human HepG2 cells (used as a toxicity counter screen).
Compounds were clustered based on structural similarity and
scored based on a variety of properties: their activity against T.
b. brucei, rate and reversibility of action in parasite growth
inhibition, and predicted CNS penetration as predicted by the
multiparameter optimization (MPO) score. These properties
were folded into a composite score to help prioritize starting
points for medicinal chemistry optimization.18,23 One of these
clusters contained a pyrazolo[1,5-b]pyridazine; a representa-
tive compound is shown in Table 1. Its properties are listed,
including those known to influence drug absorption,
distribution, metabolism, and excretion (ADME), such as
human liver microsome (HLM) and rat hepatocyte (RH)
intrinsic clearance (Clint), thermodynamic aqueous solubility
(aq sol.), and human plasma protein binding (PPB).
On the basis of the properties of 1, this class of pyrazolo[1,5-
b]pyridazines was considered a promising starting point for
treatment of both stages 1 and 2 of HAT according to the
published target product profile.24,25 This scaffold had already
been investigated for activity against serine/threonine kinase
(Stk1) in Staphylococcus aureus and for three human kinases:
glycogen synthase kinase 3β (GSK-3β) and cyclin dependent
kinases (CDK) 2 and 4.26−28 This was unsurprising as the
compound screening set used in the HTS had been selected
from a library of known kinase inhibitors, and homologs of
both GSK-3 and CDK have been identified in T. brucei as
potential targets for drug discovery.21,29
With this information, we set out to answer the following
questions. First, would we be able to discern a difference
between the series activity against T. b. brucei cells and human
enzymes GSK-3β, CDK-2, and CDK-4 by utilizing available
data for compounds in this class? Second, would under-
standing this difference enable us to design compounds with
improved activity against T. b. brucei and reduced potency
against these human kinases? Third, would compounds from
this class demonstrate efficacy in mouse models of
trypanosome infection? While we used known human kinase
inhibitor data to help guide our molecular design, we did not
infer anything about the parasitic target from this information,
as previous work optimizing for activity against T. brucei GSK-
3 has demonstrated antiparasitic activity to have arisen from a
multitarget effect.30
■ RESULTS
Selectivity. In order to assess the difference in compound
potency between T. b. brucei and GSK-3β, CDK-2, and CDK-
4, we evaluated previously reported compounds from the
original HTS (and synthesized a set of previously reported
analogs) with potency data against the three human kinases to
see if we could find any difference in the selectivity profiles.26,31
A synthetic strategy was devised (Scheme 1) that would allow
for late stage derivatization at the three positions of principal
interest (R1−R3, as shown in 8). Starting from 2,4-
Table 1. Representative Hit from the T. b. brucei HTS18,a
targeted properties 1
T. b. brucei pEC50 >7.5 8.2 ± 0.02
MRC5 pTC50 <5 <4.3 ± 0.00
HepG2 pTC50 <5 <4.0 ± 0.00
aq sol. (μM) >10 <0.1
MW ≤360 310
cLogP ≤3 2.8
cLogD ≤2 3.6
MPO score ≥4 5.1
RH Clint* ≤9 66
HLM Clint** ≤5 210
PPB (%) ≤95 98
aaq sol. = aqueous solubility. MW = molecular weight. MPO =
multiparameter optimization. RH = rat hepatocyte. HLM = human
liver microsome. PPB = plasma protein binding. ∗ = (μL/min)/106
cells. ∗∗ = (μL/min)/mg protein.
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dichloropyrimidine (5), a Sonogashira coupling was employed
with trimethylsilylacetylene. Subsequent silyl deprotection with
potassium hydroxide yielded 2-chloro-4-ethynylpyrimidine 6b.
Pyridazine 4 was reacted with hydroxylamine-O-sulfonic acid
(HOSA) to generate a 1-aminopyridizinium ion in situ, which
was then reacted with 6b in a [3 + 2] cycloaddition reaction to
form the 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazine
intermediate 7. Subsequent nucleophilic aromatic substitution
or palladium-mediated cross-coupling provided the corre-
sponding product 8.32
A previously reported crystal structure of a pyrazolo[1,5-
b]pyridazine, 9 (Figure 1a), bound into CDK-2 (PDB code
3EID) (Figure 1b and 1c), indicated that substitution at the R1
and R2 positions gave the best chance to improve selectivity,
due to the increased interaction with the binding pocket at
these positions, while the R3 position was solvent exposed, and
the binding pocket would be less sterically restrictive of the
molecule.31 Previously reported docking of a pyrazolo[1,5-
b]pyridazine into a GSK-3β crystal structure (PDB code
1GNG) predicted a similar binding mode.26,31 Available IC50
data against all three enzymes indicated that substitution at any
of these three positions could cause significant shifts in
potency, but the largest decreases in potency came with
substitution at the R1 and R2 positions. Armed with the
published human kinase selectivity data, we compared
compounds from the HTS and resynthesized a selected set
of analogs from the literature. We sought to identify which
substitutions could provide analogs with divergent activity for
T. b. brucei over GSK-3β, CDK-2, and CDK-4 (Table 2).
Substitution at the R1 position caused varying shifts in
potency between T. b. brucei and the human kinases of interest.
In general, substitution at this position led to a significant loss
in potency against CDK-2, an observation that is consistent
with the literature.26 While substituting R1 with 4-
(trifluoromethyl)phenyl (10f) caused a 100-fold decrease in
potency against T. b. brucei (compared with 10e), there was a
much greater impact on the potency against GSK-3β and
CDK-2, both of which exhibited a >1000-fold decrease.
Similarly, substitution with 4-methoxyphenyl (10q) caused a
10-fold decrease in the potency against T. b. brucei (compare
with 10o); however the potency against GSK-3β and CDK-2
was decreased by >10 000-fold. Replacement of the phenyl ring
with a (smaller) cyclopropyl group (10n) also resulted in a
slight decrease in the potency against T. b. brucei relative to the
unsubstituted analog (10m). This loss in potency was again
much less dramatic than observed against GSK-3β and CDK-2
(between 3.5 and 4 log units). This indicated that while small
Scheme 1. Synthesis of Pyrazolo[1,5-b]pyridazine Analogsa
aReagents and conditions: (a) POCl3, 80 °C, 1 h, 70%; (b) NaO
tBu,
MeOH or morpholine, n-BuOH, 80 °C, 12 h, 60−100%; (c) HCCR1,
CuI, Pd(PPh3)2Cl2, TEA, THF, 50 °C, 12 h, 19−61%; (d) KOH,
MeOH, rt, 30 min, 94%; (e) 4, hydroxylamine-O-sulfonic acid, KOH,
NaHCO3, H2O, DCM, 70 °C → rt, 12 h, 40−84%; (f) NH2R3, n-
BuOH, 150 °C, 2 h, 11−90%; (g) NH2R3, Pd(OAc)2, BINAP or
xantphos, Cs2CO3, dioxane, 160 °C, 1 h, 6−70%.
Figure 1. Previously reported crystal structure of pyrazolo[1,5-
b]pyridazine compound, (R)-1-(dimethylamino)-3-(4-((4-(6-
morpholinopyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)amino)-
phenoxy)propan-2-ol, 9 (green, stick representation), bound in
human CDK-2 (gray, surface/wire representation) (PDB code
3EID):31 (a) structure of 9; (b) binding mode of 9 within the
binding pocket, highlighting key hinge binding interactions with LEU-
83; (c) binding position of 9 showing ligand−surface interactions
within 5 Å, displaying position of R1 inside the binding pocket.
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Table 2. Pyrazolo[1,5-b]pyridazine Analogs with Published Human Kinase Data, Compared with Whole Cell T. b. brucei
Potency Dataa
aCompounds without published data against a human kinase data were left blank. *Standard error of mean (SEM) within 0.17.
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substituents were tolerated, there was a sharp decrease in
activity against T. b. brucei as R1 became larger. In sum, we
were able to demonstrate the potential of compounds with T.
b. brucei activity that is divergent from human GSK-3β and
CDK-2 activity particularly when substituted at R1 or R2.
Substitution at the R2 position with a morpholine group
(10d) led to an equipotent compound against T. b. brucei
relative to the unsubstituted analog (10c), with a concomitant
and significant decrease in activity against both GSK-3β and
CDK-4 (∼10× against both). The presence of a methoxy at
the R2 position (10j) led to a dramatic decrease in activity of
the series against T. b. brucei; it also contributed to a complete
loss of activity against CDK-4.
Substitution at R3 caused a significant shift in the potency of
the series against T. b. brucei. Analogs with an alkyl attachment
at the R3 position (10a, 10b, 10c, 10d) showed moderate
inhibition of T. b. brucei, though aryl substituents (summarized
in Figure 2) caused a noticeable increase in potency against T.
b. brucei (typified by 10e). While these changes caused
significant shifts in the activity of the compounds, they did not
provide any tangible selectivity improvement against the three
human kinases. Substitution of the aryl ring at the 3-position
with electron withdrawing groups (EWG) yielded the most
potent compounds against both T. b. brucei and the human
enzymes (1, 10h). Electron donating groups (EDG) at the 3-
position (10i) did not cause any significant shift in the
potency, though disubstitution at the 3- and 5-positions (10k,
10l) caused a noticeable decrease in activity against T. b. brucei.
Disubstitution at the 3- and 4-positions of the phenyl ring
(10m, 10r) did not seem to cause this shift in potency; this
trend implied there were less steric restraints on the 4-position
of the R3 ring for activity against both T. b. brucei cells and the
human enzymes. This observation is consistent with the crystal
structures for human GSK-3β and CDK-2, wherein the 4-
position of the ring points out of the binding pocket.26,31
Curious as to the role of the pyrazolo[1,5-b]pyridazine head
group in the activity of the cluster, a series of analogs was
prepared to elucidate the impact of the nitrogen atom
positioning within the head group upon T. b. brucei activity.
The pyrazolo[1,5-a]pyridine head was synthesized via
Sonogashira reaction using trimethylsilylacetylene (Scheme
2). Following desilylation, a [3 + 2] dipolar cycloaddition was
effected using a 1-aminopyridinium ion generated in situ to
give 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine (11)
in moderate yield. Subsequent nucleophilic aromatic sub-
stitution gave the desired products.
As Table 3 shows, replacement with the pyrazolo[1,5-
a]pyridine head caused a decrease in potency for all four
analogs compared to their matched pyrazolo[1,5-b]pyridazine
counterparts. Compound 12a showed the smallest decrease in
potency compared to 10c but was still 2-fold less potent. The
aromatic substituents at the R3 position were a minimum of 7-
fold less active against T. b. brucei (12b compared to 10e), all
the way up to 15-fold less active (12d compared to 1). Due to
this decrease in activity and no-tangible gain in the ADME
profile of the series, we turned our attention to replacing the
nitrogen atoms in the pyrimidine ring.
The crystal structure and docking study for both GSK-3β
and CDK-2 indicated that the key hinge binding interaction
(highlighted in Figure 1b) with the series occurred between
the pyrimidine nitrogen and amine at the R3 position.26,31 If
altering or removing this interaction did not cause a significant
loss in potency against T. b. brucei, it would likely result in a
large selectivity improvement over the human enzymes. As
such, we set out to remove or replace the pyrimidine and
amine nitrogens. The pyridine analogs (shown in Table 4)
were prepared as shown in Scheme 1, starting from the
corresponding ethynylpyridine. However, this route proved
unsuccessful for the phenyl derivatives, so a new synthetic
route was employed, shown in Scheme 3. Starting from
pyridazine, a [3 + 2] dipolar cycloaddition was performed with
methyl propiolate. The subsequent product was saponified
using potassium hydroxide to give the corresponding acid. A
Hunsdiecker-like transformation provided the bromide, which
was then used to perform a Suzuki-cross coupling to install the
phenyl ring.33
Both pyrimidine nitrogen atoms were deemed crucial for
potent activity (Table 4), as removal of either (18d, 18b)
resulted in a >10-fold potency loss compared to the original hit
(1). Removal of both nitrogen atoms (17) resulted in an
additional decrease in potency. Removal of the hydrogen bond
donor (HBD) and R3 ring (16a, 18a, 18c) resulted in a total
loss of activity against T. b. brucei, though it also corresponded
with a substantial increase in the solubility of all three
compounds.
Given the crystal structures of GSK-3β and CDK-2, as well
as the selectivity gained from the presence of a cyclopropyl
group at the R1 position in 10n, we performed a methyl scan
around the pyrimidine ring to assess potency changes against
T. b. brucei. The 5 and 6 positions on the pyrimidine ring were
positioned in a similar part of the binding pocket in the GSK-
3β crystal structure as the cyclopropyl group of 10n. Since
substitution pointing into the binding pocket of the human
enzymes had given selectivity for 10n, we hoped that
substitution off of the pyrimidine ring would give us a similar
Figure 2. Preliminary structure−activity relationship (SAR) trends for
substitution of aromatic rings at R3 position.
Scheme 2. Synthesis of Pyrazolo[1,5-a]pyridine Analogsa
aReagents and conditions. (a) pyridine, hydroxylamine-O-sulfonic
acid, KOH, NaHCO3, H2O, DCM, 70 °C → rt, 12 h, 51%; (b)
NH2R
3, K3PO4, XPhos, Pd2(dba)3, toluene, 110 °C, 12 h, 22%; (c)
NH2R
3, n-BuOH, 110 °C, 12 h, 40−88%.
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selectivity advantage. By use of the same chemistry shown in
Scheme 1, two analogs were prepared from the starting
pyrimidines with methyl groups at the desired positions. As
shown in Table 5, substitution at the 5-position of the
pyrimidine ring (19b) lowered the activity of the series by 10-
fold compared to the original hit (1) whereas substitution at
the 6-position (19a) resulted in a complete loss of activity. In
the published crystal structures and docking models against
GSK-3β and CDK-2, these two positions on the pyrimidine
ring had pointed into the same part of the binding pocket as
Table 3. Effect of Pyrazolo[1,5-a]pyridine Head on T. b. brucei Potency ADME Propertiesb
aCompound detected only in first sample. b∗ = SEM within 0.05. ∗∗ = (μL/min)/106 cells. ∗∗∗ = (μL/min)/mg protein. nd = not determined.
Table 4. T. b. brucei Activity of the Pyrimidine Replacement Analogs and the Associated ADME Dataa
a∗ = SEM within 0.08. ∗∗ = (μL/min)/106 cells. ∗∗∗= (μL/min)/mg protein. ∗∗∗∗ = SEM within 0.02.
Scheme 3. Synthesis of Pyrimidine Replacement Analogs Containing Phenyl Ringa
aReagents and conditions: (a) pyridazine, hydroxylamine-O-sulfonic acid, KOH, NaHCO3, H2O, DCM, 70 °C→ rt, 12 h, 71%; (b) NaOH, H2O,
70 °C, 1 h, 37%; (c) NBS, DMF, 25 °C, 3 h, 79%; (d) R(BOH)2, Pd(dppf)Cl2·DCM, K2CO3, 3:1 dioxane/H2O, 130 °C, 1 h, 15−72%; (e) 3-
aminobenzonitrile, Pd(OAc)2, xantphos, Cs2CO3, dioxane, 160 °C, 1 h, 47%.
Journal of Medicinal Chemistry Article
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R1.26,31 While substitution at this position may have resulted in
increased selectivity against the human enzymes, the loss in
activity against T. b. brucei indicated that there was no room for
substitution on this portion of the scaffold.
ADME Optimization. Armed with the knowledge of the
substitutions that were tolerated at the R1 and R2 positions, our
attention turned to the exploration of the SAR around the R3
position of our hit compound, 1, with the view to determining
which R3 substituents would provide the most favorable
combination of potency and ADME properties (Table 6).
Compounds 20a and 20b demonstrated the importance of the
HBD for potency against T. b. brucei. Removal of the nitrile
(10e) did not cause any significant change in the ADME
properties of the series, though replacement with a
trifluoromethyl (20c) improved the clearance of the series in
both RH and HLM, though it also resulted in a 4.4-fold
decrease in potency against T. b. brucei. ortho-Methyl
substitution of the phenyl ring (10g) provided a substantial
improvement in the aqueous solubility; comparison of 10g’s
melting point (mp = 177−178 °C) to the melting point of 10e
(mp = 207−209 °C) suggested that this increase in solubility
was due to the disruption of the crystal packing of the
compound. However, 10g showed a decrease in the activity
against T. b. brucei. To further explore whether ortho-
substitution was a viable route to improve the ADME
properties while maintaining potency, we investigated
compounds with a fluorine atom at either the 2- or 6- position
of the ring (20d, 20e). These analogs did not show any
significant improvement in the solubility of the series
(compared with 1). Next, a number of heterocyclic replace-
ments for the R3 phenyl group were prepared, including
pyridines (20f, 20g, 20h), pyrimidines (20i), and pyridazines
(20j). The 3-pyridyl analog (20g) showed a 3.5-fold reduction
in the potency compared to 1 but showed improvements in the
aqueous solubility and RH Clint (though HLM Clint was still
high). As blocking the 4-position of the ring (10s) had
previously shown reduced HLM clearance, 20k was prepared,
though it demonstrated increased HLM and RH clearance over
20g. The pyrimidine analog (20i) displayed further improve-
ment in solubility and HLM clearance, though this was at a
4.9-fold cost to potency when compared to 20g.
In addition to aryl substituents, a variety of alkyl substituents
were explored at the R3 position, as increasing the sp3 carbon
content has been previously shown to improve the aqueous
solubility of a chemical series.34,35 As the steric bulk and
lipophilicity of the compounds increased, an increase in
potency against T. b. brucei was observed; however this
increase in potency typically came with a significant reduction
in solubility. Compound 20q was the most active of the
compounds against T. b. brucei but demonstrated low solubility
(2 μM) and high intrinsic clearance against both RH and
HLM. Introduction of a polar group at the 4-position was
trialed as this region was known to be solvent exposed in
human enzymes and we had observed a similar SAR
relationship between T. b. brucei and the human targets at
the R3 position.26,31 The introduction of a trans-alcohol (20r)
greatly improved the ADME profile while simultaneously
maintaining the activity against T. b. brucei (pEC50: 6.8) as
seen with 20q.
Comparison of the initial human kinase and T. b. brucei data
indicated that substitution at the R1 position provided a
promising opportunity to obtain selectivity. We also wanted to
evaluate the impact that substitution at this position would
have on the ADME properties of the series. Compound 21d
demonstrated submicromolar activity against T. b. brucei and
an improved ADME profile (Table 7), and the corresponding
methyl ether (21e) showed that the presence of the HBD did
not have a significant effect on the potency. The secondary
alcohol (21f) and the isopropyl (21g) derivatives were
equipotent, though a slight boost in potency was observed
with the cyclopropyl (21h), suggesting that there are steric
limitations. Compound 21h also demonstrated an improve-
ment in the solubility and clearance compared to 1.
Additionally, the cyclopropyl group at the R1 position was
previously shown to cause a total loss of activity against GSK-
3β and CDK-2 (Table 2, 10n).
Substitution at the R2 position with a morpholine or
methoxy had previously shown a reduction in activity versus
human CDK-2 and CDK-4; as such, we wanted to assess
whether these substituents could also help improve the ADME
properties of the series (Table 8). The morpholine was found
to have no effect on the potency of the series (22c vs 1),
though small improvements in the HLM clearance were
observed. The methoxy group was found to lower potency by 1
log unit (22d vs 1) against T. b. brucei but had previously been
reported to lead to a total loss in activity against CDK-4 (Table
2, 10j).
Given the observed trends in selectivity, activity, and ADME,
we set out to make a series of combination analogs (Table 9).
For the R1 position we examined the cyclopropyl group and
primary alcohol as these groups were small enough to not
significantly impact the potency of the molecule and could
potentially provide a selectivity advantage. We selected three
different R3 groups: 3-aminobenzonitrile, 3-aminopyridine, and
trans-4-aminocyclohexanol based on the observed potency and
ADME properties they displayed.
The series of matched analogs detailed in Table 9 gave
further insight into the SAR of the cluster. At the R1 position,
Table 5. Analogs for Methyl Scan of Pyrimidinea
compd X Y T. b. brucei pEC50
a aq sol. (μM) log D7.4 RH Clint** HLM Clint*** PPB (%) MRC5 pTC50
19a -H -CH3 <4.4 0.8 4 17 56 97 <4.3
19b -CH3 -H 7.0 0.2 4 80 170 99 <4.3
a∗ = SEM within 0.09. ∗∗ = (μL/min)/106 cells. ∗∗∗ = (μL/min)/mg protein.
Journal of Medicinal Chemistry Article
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Table 6. T. b. brucei Activity and ADME Properties of Analogs with Substituents at the R3 Positionb
aLow recovery/low stability. b∗ = SEM within 0.14. ∗∗ = (μL/min)/106 cells. ∗∗∗ = (μL/min)/mg protein. ∗∗∗∗ = SEM within 0.17. nt = not
tested. nd = not determined.
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analogs with a cyclopropyl group (23c, 23g, 23l) were more
potent than the matched pair analogs containing a primary
alcohol (23b, 23f, 23m, respectively). In addition, comparison
of 23g and 23l to their matched pair analogs with no
substitution at the R1 position (23e and 23k, respectively)
showed no decrease in potency. Interestingly this trend was
not observed with compounds containing a morpholine group
at the R2 position, as 23h was over 10-fold less active than its
unsubstituted matched pair 23i. It should also be noted that
the unsubstituted analogs at R1 showed the lowest clearance
against both RH and HLM, indicating that R1 substituents may
be a site of metabolism.
At the R2 position, analogs with a methoxy group 23a and
23g were more potent than their morpholine matched pair
analogs 23b and 23h, respectively. The reverse of this trend
was seen with 23k compared to 23j (and 22c vs 22d
previously). This reversal in trends seems to further indicate
that substitution at the R1 position could have an impact on
the compound−target interactions at the R2 position. Analogs
with substitution at R1 appear to be more potent with a
methoxy group at R2, while analogs without substitution at R1
were more potent with the morpholine. Compound 23g, with
a methoxy group at R2, showed an increased potency in
comparison to the analog with no substitution, 23d.
Compound 23d was equipotent against T. b. brucei with the
morpholine derivative, 23h. This increase in potency from the
introduction of a methoxy group can also be observed
comparing 21d (Table 7) to 23a, where 23a was 4-fold
more active. Overall the morpholine group was better for
controlling the clearance of the series with matched analogs
(23h and 23j) containing the morpholine showing lower RH
and HLM clearance than the methoxy counterparts (23g and
23k), though all R2 analogs showed higher clearance and were
less soluble than the unsubstituted analogs (23d and 20r).
A subset of these combination molecules was sent for single
point inhibition assays against all three human kinases (Table
10). Analogs were prioritized based on their predicted
selectivity. As expected, 23i and 23e displayed the highest
Table 7. T. b. brucei Activity of Analogs with a Substituent at the R1 Positiona
a∗ = SEM within 0.08. ∗∗ = (μL/min)/106 cells. ∗∗∗ = (μL/min)/mg protein. ∗∗∗∗ = SEM within 0.03. nt = not tested.
Table 8. T. b. brucei Activity and Associated ADME Profile of Analogs with a Substituent at the R2 Positionb
aLow MS/MS signal. b∗ = SEM within 0.13. ∗∗ = (μL/min)/106 cells. ∗∗∗ = (μL/min)/mg protein. nd = not determined. nt = not tested.
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percent inhibition of all three human enzymes, reaffirming the
need for substitution at R1 to provide selectivity. This was also
evident when examining the selectivity trend for CDK-4, as any
substitution at R1 caused a significant decrease in the activity
against the enzyme. At R1 the primary alcohol (23a, 23b) was
generally less active than the cyclopropyl (23d, 23g, 23h)
against CDK-2. The morpholine group did appear to decrease
affinity for CDK-2 provided there was substitution at R1 (23h,
23b). For GSK-3β the cyclopropyl group at R1 provided the
greatest decrease in percent inhibition (23d, 23h); however
the morpholine at R2 seemed to increase potency against the
human enzyme. The most selective of these compounds, 23a,
displayed less than 50% inhibition against all three targets;
however due to a poor ADME profile, it was not considered for
further evaluation.
With evidence of what was required to obtain selectivity in
the series, we set out to determine whether the pyrazolo[1,5-
b]pyridazine head would be efficacious in an animal model of
infection. On the basis of the observed SAR and ADME data,
summarized in Figure 3, we prioritized 20r and 20g for further
investigation. Further studies showed that both 20r and 20g
were stable in mouse plasma (Table S3, Supporting
Information), were not substrates of the cytochrome P450
isozyme 3A4, and did not induce testosterone metabolism in
Table 9. T. b. brucei Activity and ADME Properties for a Series of Combination Analogs, Combining Various R1, R2, and R3
Substituentsc
aPoor MS response. bNo compound detected. c∗ = SEM within 0.13. ∗∗ = (μL/min)/106 cells. ∗∗∗= (μL/min)/mg protein. nd = not determined.
nt = not tested.
Table 10. % Inhibition of Selected Analogs at 1 μM against
Human Kinases CDK-2, CDK-4, and GSK-3βa
compd
T. b. brucei
pEC50*
CDK-2
cyclin A
(%)
CDK-2
cyclin E
(%)
CDK-4
cyclin D3
(%)
GSK-3β
(%)
23a 7.2 47 29 1 49
23b 6.8 46 54 32 75
23d 6.8 76 70 21 21
23e 7.2 84 84 69 89
23g 7.2 84 77 25 65
23h 6.8 67 49 26 34
23i 7.9 89 87 90 81
a∗ = SEM within 0.13.
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CYP450 3A4 (Table S4, Supporting Information). Both
compounds were also found to be permeable in Caco-2 cells
and were not actively effluxed (Table S5, Supporting
Information).
A small number of compounds were assessed to see if they
were still fast acting and parasiticidal, including 20r and 20g
(Table S6, Supporting Information). Using a set of criteria
previously disclosed,18 inhibitory properties of both com-
pounds were assessed at set time points (Figure 4); we defined
fast-acting compounds as having pEC50 ≥ 6 after 18 h of
incubation. Given this definition, 20g was fast-acting and 20r
was slow acting. In parallel, washout assays were performed to
assess whether the compounds were cidal or static. The
compounds were incubated for 18 h with T. b. brucei and then
washed out, and the parasite was incubated for 72 h before the
wells were assayed to determine pEC50 values. Compound 20g
was deemed cidal as it demonstrated pEC99 ≥ 6 following the
washout assay, whereas 20r was not cidal.
Both 20g and 20r were advanced to pharmacokinetic (PK)
studies in mice, 20r for its superior ADME profile, and 20g for
its rate of action, cidal activity, and high potency. Although
neither compound contained structural features that were
indicative of selectivity over human GSK-3β, CDK-2, and
CDK-4, we theorized that their ADME profiles and activity
gave the highest probability of providing proof of concept
efficacy. With the knowledge that inhibitors of GSK-3β have
been shown to have no negative effect in in vivo studies and
lack of activity observed against human MRC5 cells for either
20g and 20r, we believed that there may be an acceptable
therapeutic window.19,36
Following a 10 mg/kg intraperitoneal dose (ip) into female
NMRI mice, 20r (Figure S2, Supporting Information) showed
low whole blood exposure, with levels above the EC50 value
(152 nM or 47 ng/mL) for <4 h following ip administration.
In addition, the compound levels were below the lower limit of
quantitation in the CNS after 4 h. We therefore deprioritized
20r for efficacy studies.
Compound 20g demonstrated much better BBB penetration
with similar concentrations in both the blood and brain
(Figure 5). In addition, although the compound displayed a
short half-life (t1/2 = 0.68 h), blood and brain concentrations
were >10 × EC50 value (20 nM or 6.1 ng/mL) for the entire
duration of the study. Given the window for activity, as well as
BBB penetration, 20g was taken forward into an efficacy study.
For the efficacy study, mice were infected with T. b. brucei
STIB795 and 3 days postinfection 20g was administered at 10
mg kg−1 day−1 ip for 5 consecutive days with daily monitoring
of parasitemia levels. A significant reduction was observed in
parasitemia for four of six mice, resulting in parasite
concentrations dropping below detectable levels by day 4 of
treatment (Table S10, Supporting Information). Despite the
reduction of parasitemia, 20g showed a negligible improve-
ment in the survival rate of the mice compared with the control
group, likely due to the toxicity of the compound, as mice
presented with conjunctivitis, lacrimation, facial inflammation,
in addition to an inflamed liver and kidneys (Figure 6).
Due to the toxicity observed from the efficacy study, we
deemed it pertinent to examine the wider kinase selectivity of
20g, profiling it against a panel of human kinases (Figure 7).
Of the 47 kinases 20g was profiled against, 14 showed greater
than 50% inhibition at 1 μM. Unsurprisingly, given the lack of
Figure 3. Summary of the SAR and structure−property relationships (SPR) for the pyrazolo[1,5-b]pyridazines.
Figure 4. Rate of action of 20g and 20r, comparing pEC50 values
against T. b. brucei following defined periods of incubation with the
compound. Compounds with pEC50 ≥ 6 at 18 h were deemed fast
acting (shown with a darkened line).
Figure 5. Peripheral blood levels of 20g after ip administration to
female NMRI mice (n = 3) at a target dose of 10 mg/kg in 1%
DMSO, 20% Captisol in water. Individual values for each time point
are represented in the plot.
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substitution around R1 and R2, 20g still showed potent
inhibition of GSK-3β, CDK-2, and CDK-4. Further efforts in
the optimization of this series would need to address this
toxicity. Given the improvement in the selectivity of 23a, a
more thorough investigation of substituents at R1 and R2 is
warranted. The difference in toxicity, shown in Table S11,
Supporting Information, against L6 (20g pTC50 > 6.2, 23a
pTC50 < 4.3) and THP-1 (20g pTC50 > 6.2, 23a pTC50 < 4.3)
indicates that these may be better cell lines to use when
optimizing for toxicity.
A selection of compounds from this cluster was also
screened against T. cruzi (Table S11, Supporting Information),
Leishmania donovani (Table S11, Supporting Information), and
adults of the flatworm pathogen, Schistosoma mansoni (Table
S12, Supporting Information). Compound 10e was the most
active compound against T. cruzi, although this was
accompanied by poor selectivity versus L6 cells. While S1a
was the most active against L. donovani and had a good
selectivity profile. Further optimization to understand the SAR
versus T. cruzi and L. donovani is warranted. Against S.
mansoni, most compounds were inactive, although 10s and S1k
showed similar activities characterized by a marked decrease in
movement and an inability by the parasite to adhere to the
bottom of the floor of the assay well with its oral and ventral
suckers. Apart from these two compounds, this cluster does
not warrant further investigation as a source of antischistoso-
mal agents.
■ CONCLUSIONS
Starting from a screen of 42 444 known kinase inhibitors, we
set out to optimize a pyrazolo[1,5-b]pyridazine scaffold for the
treatment of HAT. Using published SAR data against known
human kinases GSK-3β, CDK-2, and CDK-4, we were able to
design an analog, 23a, which showed selectivity against all
three human targets. As 23a did not have an ADME profile we
deemed acceptable, 20g was taken forward into a mouse model
to determine whether the series as a whole had potential to be
effective in vivo. Compound 20g was selected because it was
fast acting, parasiticidal, had desirable ADME properties close
to our targeted values, and showed good BBB penetration in
the PK study. Compound 20g demonstrated acceptable brain
concentrations and levels in excess of 10 × EC50 for 4 h in the
PK study and demonstrated a reduction in parasitemia in four
out of the six mice tested. Although 20g’s toxicity in vivo did
not warrant further investigation, it highlights the promise of
this series as anti-HAT agents.
■ EXPERIMENTAL SECTION
Strains and Media. Bloodstream Trypanosoma brucei brucei Lister
427 was cultured in Hirumi’s modified Iscove’s medium (HMI-9),
supplemented with 10% heat-inactivated FBS, at 37 °C and 5% CO2
in T-25 vented flask (Corning).
MRC5-SV2 cell line (SV40-transformed human lung fibroblast cell
line) was cultured in DMEM medium supplemented with 10% FBS at
37 °C and 5% CO2 in T-75 vented flask (Corning).
The T. cruzi Tulahuen C4 strain, expressing the β-galactosidase
gene (LacZ) and L6 rat skeletal muscle cells, used as host cells, were
cultured in RPMI-1640 supplemented with 10% iFBS, 2 mM L-
glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37
°C and 5% CO2.
Leishmania donovani MHOM/ET/67/HU3 cells with the luciferase
gene integrated into the parasite genome were grown at 28 °C in
RPMI 1640-modified medium (Invitrogen) supplemented with 20%
FBS with 100 mg/mL of hygromycin B.37
The human myelomonocytic cell line THP-1 was grown at 37 °C
and 5% CO2 in RPMI-1640 supplemented with 10% iFBS, 2 mM
glutamate, 100 U/mL penicillin, and 100 mg/mL streptomycin. 3
×104 THP-1 cells per well in 96-well plates were differentiated to
macrophages with 20 ng/mL of PMA treatment for 48 h followed by
24 h of culture in fresh medium.
Maintenance of the Schistosoma mansoni life cycle (NMRI isolate),
the preparation of adult worms (≥42-days-old), and phenotypic
screens with test compounds were as described.38−40
Preparation of Compound Plates. For dose−response experi-
ments, compound plates were prepared for each analogue by serial 3-
fold dilutions in 100% DMSO. Five concentration points (mammalian
cytotoxicity) or ten concentration points (parasite growth inhibition)
were made in a 96-well transparent Nunclon plate. Internal control
(pentamidine) is included randomly for Trypanosoma brucei assay
plates.
Trypanosoma brucei Growth Inhibition Assay. In order to
determine the T. b. brucei EC50 values, an amount of 4 μL per well
from compound master plates was dispensed into a new plate and an
amount of 96 μL of HMI-9 per well was added to generate a 4%
DMSO intermediate plate. Mid-log phase growth T. b. brucei was
diluted to a working cell density of 2750 cells/mL and 90 μL/well
Figure 6. Effect of 20g on trypanosomes in a mouse efficacy model of
HAT. Percent (%) survival rate of mice dosed ip at 10 mg kg−1 day−1,
compared to the control vehicle.
Figure 7. Percent (%) inhibition at 1 μM 20g against human kinases.
Line is drawn to show 50% inhibition of enzymes. Kinases showing
significant inhibition (above 50%) are listed on the X-axis. We define
significant inhibition as >50% inhibition at 1 μM (red line), weak to
moderate inhibition to be between 25% (green line) and 50%, and
insignificant inhibition to be <25%. For all values of inhibition see
Table S9, Supporting Information.
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dispensed into 96-well flat-bottom transparent assay plates (Nunc)
where an amount of 10 μL/well from intermediate plates was added.
Final top concentration of compounds was 40 μM in 0.4% DMSO per
well.
Assay plates were incubated for 72 h at 37 °C and 5% CO2. Four
hours prior to the end of the incubation, 20 μL of a 440 μM resazurin
solution in prewarmed HMI-9 was added to each well and incubated
for another 4 h. Fluorescence was then measured in an Infinite F200
plate reader (Tecan) at 550 nm (excitation filter) and 590 nm
(emission filter). A four-parameter equation was employed to fit the
dose−response curves and determine the EC50 using the SigmaPlot
13.0 software. Assays were performed in duplicate at least twice to
achieve a minimal n = 3 per dose response.
Rate of Action Assays. Mid-log T. brucei brucei cultures were
diluted to the required cell density, according to the different
incubation time points described. An amount of 90 μL per well was
dispensed in final assay plates Nunclon 96-well flat bottom Solid
White, and an amount of 10 μL of intermediate plates was added to
each well, as described before. Four sets of assay plates were arranged
to assay in order to be sequentially stopped at each indicated time
point. Top and bottom rows were dismissed for compound assay, to
reduce evaporation effects.
Plates were incubated at 37 °C and 5% CO2 for the indicated time
points; incubation was stopped by addition of 10 μL of prewarmed
Cell Titer Glo reagent (Promega), and after shaking the plates were
incubated at room temperature for 10 min to allow the signal to settle.
Plate luminescence was read on an Infinite F200 plate reader (Tecan),
and raw data were processed and analyzed as previously described.
Reversibility Assays. Mid-log T. brucei brucei cultures were
adjusted to a working density of 3500 cell/mL. An amount of 90 μL
per well was dispensed in final assay plates 96-well transparent
Nunclon plates, and an amount of 10 μL of intermediate plates was
added to each well, as described before. Top and bottom rows were
dismissed for compound assay, to reduce evaporation effects.
Plates were incubated at 37 °C and 5% CO2 for 18 h; once drug
exposure was finished, plates were spun for 5 min at 500 rpm and
room temperature to allow cells to settle at the well bottoms. 95 μL of
media was replaced with fresh prewarmed media, and the process was
repeated 3 times. Finally, an amount of 10 μL of each well was seeded
in a new microtiter plate with 90 μL of fresh prewarmed media, in
duplicate. Plates were incubated for 72 h, and viability was determined
by resazurin reduction as previously described.
Cytotoxicity Assay in MRC5 Cells. Intermediate plates were
made as described, adding 95 μL of DMEM complete media to 5 μL
of compound per well setting a 5% DMSO amount.
The log-phase MRC5 cells were removed from a T-75 TC flask
using TrypLE Express (Thermo) and dispersed by gentle pipetting.
Cell density was adjusted to working concentration in prewarmed
DMEM medium: 25 000 cells in 90 μL of culture were plated in 96-
well transparent Nunclon plates and allowed to settle for 24 h at 37
°C and 5% CO2. After settling incubation, an amount of 10 μL of
fresh made intermediate plate was added per well: final maximal
concentration for compounds was 50 μM in 0.5% DMSO per well.
Plates were incubated for 48 h at 37 °C and 5% CO2. 4 h prior to
fluorescence measurement, 20 μL of 500 μM resazurin solution was
added. Fluorescence was read in an Infinite F200 plate reader (Tecan)
at 550 nm (excitation filter) and 590 nm (emission filter).
A four-parameter equation was used to fit the dose−response
curves and for determination of EC50 by SigmaPlot 13.0 software.
Assays were performed in duplicate at least twice for positive
compounds, to achieve a minimal n = 3 per dose response.
β-D-Galactosidase Transgenic T. cruzi Assay. A Thermo
Scientific Multidrop Combi dispenser (MTX Lab Systems, Vienna,
VA) was used to dispense 90 μL of T. cruzi amastigote-infected L6
cell culture (4 × 103 infected L6 cells per well) into 96-well Corning
assay plates (Corning Inc., Corning, NY) already containing 10 μL of
the compounds to be screened and controls. The plates were
incubated at 37 °C for 96 h. Then, 30 μL of 100 μM CPRG and 0.1%
NP40 diluted with PBS were added to each well, and the plates were
incubated for 4 h at 37 °C in the dark. Absorbance at 585 nm was
measured in a Vmax kinetic microplate reader (Molecular Probes).
Compound activities were normalized using the in-plate negative
(benznidazole at 10 μg/mL) and positive (0.2% DMSO) growth
controls.
Resazurin-Based L6 Assay. An amount of 100 μL per well of
culture medium containing the compounds and controls was added to
L6 cells previously cultured (4 × 103 L6 cells per well). After 72 h at
37 °C the medium was exchanged and the viable cell number was
determined by resazurin (Sigma-Aldrich) reduction. 20 μL of
resazurin (1.1 mg/mL) was added to each well and incubated in
the dark for 2 h at 37 °C. Cell viability was estimated by measuring
the final fluorescence at 570−590 nm in an Infinite F200 plate reader
(Tecan).
Cytotoxicity Assay in THP-1. Cellular toxicity of all compounds
was determined using the colorimetric MTT-based assay after
incubation at 37 °C for 72 h in the presence of increasing
concentrations of compounds (final maximal concentration was 50
μM in 0.5% DMSO per well).41 The results are expressed as EC50
values, the concentration of compound that reduces cell growth by
50% versus untreated control cells. Assays were performed in
duplicate at least twice to achieve a minimal n = 3 per dose response.
Determination of EC50 in L. donovani. Macrophage-differ-
entiated THP-1 cells were infected at a macrophage/parasite ratio of
1/10 with stationary L. donovani promastigotes for 24 h at 35 °C and
5% CO2, and extracellular parasites were removed by washing with
PBS. Infected cell cultures were then incubated with different
compounds concentrations at 37 °C for 72 h. Luminescence was
measured using the Promega kit luciferase assay system (Promega,
Madison, WI). Assays were performed in duplicate at least twice to
achieve a minimal n = 3 per dose response.
ADME Experiment Protocols. Aqueous pH 7.4 Solubility.
Compounds are dried down from 10 mM DMSO solutions using
centrifugal evaporation technique. Phosphate buffer (0.1 M, pH 7.4)
was added and StirStix inserted in the glass vials, and shaking is then
performed at a constant temperature of 25 °C for 20−24 h. This step
is followed by double centrifugation with a tip wash in between, to
ensure that no residues of the dried compound are interfering. The
solutions are diluted before analysis and quantification using LC/MS/
MS is performed.
log D7.4. The distribution coefficient between 1-octanol and
aqueous buffer, log D, at pH 7.4, is based on the traditional shake flask
technique but with the modification of measuring compounds in
mixtures of 10 at a time using UPLC with quantitative MS to measure
the relative octanol and aqueous concentrations of compounds. The
buffer solution used is 10 mM sodium phosphate (pH 7.4). The
method has been validated for log D7.4 ranging from −2 to 5.0.
Human Plasma Protein Binding (PPB). PPB is determined
using equilibrium dialysis (RED device) to separate free from bound
compound. The amount of compound in plasma (1 mM initial
concentration in DMSO) and in dialysis buffer (pH 7.4 phosphate
buffer) is measured by LC/MS/MS after 18 h in a dialysis chamber at
37 °C. Sample levels are quantified using a seven-point calibration
curve in plasma. The fraction unbound (fu, %) is reported.
Human Liver Microsomal Clint. In vitro intrinsic clearance was
determined from human liver microsomes using a standard
approach.42 Following incubation and preparation, the samples are
analyzed using LC/MS/MS. Refined data are uploaded to IBIS and
are displayed as Clint (intrinsic clearance) in (μL/min)/mg protein.
Rat Hepatocyte Clint. In vitro intrinsic clearance was determined
from rat han Wistar hepatocytes at a final concentration of 1 million
cells/mL. The cells were preincubated at 37 °C for 15 min before
addition of test compound (as a 50 μM stock solution) to a final
concentration of 1 μM. The samples were analyzed using LC/MS/MS
at predefined time points. Refined data were uploaded to IBIS and are
displayed as Clint (intrinsic clearance) (μL/min)/1 million cells.
Calculated log P and log D Values. Both log P and log D
predictions are based on a modified version of the method43 where
the predicted partition coefficients are composed of the molecules’
atomic increments.
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Matrix Stability. For stability in mouse matrix, CD-1 is
determined at 37 °C. The assay is performed by adding 500 μM
compound solution to the matrix to achieve a final concentration of 2
μM. Following incubation for 0, 0.25, 0.5, 1, 2, and 4 h, the samples
are quenched and analyzed using LC/MS to determine the percentage
of drug remaining.
Caco-2 Permeability. The Caco-2 permeability of test com-
pounds is measured using an established protocol at Charles River
Labs. Concentration of test compounds is determined by measuring
the peak area rations at T = 0 and 2 h on the apical and basolateral
sides of the basal plate.
CYP Induction. CYP induction is measured using established
protocols at Charles River Labs. The assay is performed by adding the
test compound to the positive or negative controls, incubating for 3 h
at 37 °C, following determination of the fold-induction relative to the
vehicle control by LC/MS/MS analysis.
CYP Inhibition. CYP inhibition is measured using established
protocols at Charles River Labs. A 50 mM stock solution was
prepared and serially diluted (1.5-fold and 4-fold). This was then
combined with a buffer/cofactor/substrate solution before combining
with the human liver microsomes. The resulting mixture was
incubated at 37 °C for 30 min with gentle shaking before the
percentage inhibition was calculated relative to zero inhibition by LC/
MS/MS analysis.
For all experiments, compounds were marked as not tested if they
were not run in an assay and marked as not determined if they were
run in an assay, but the result was inconclusive.
Pharmacokinetics of 20r and 20g Following ip Admin-
istration to Female NMRI. Estimation of Brain Penetration.
Compounds 20r and 20g were dosed to two groups of NMRI female
mice animals (groups 1 and 2, n = 3; groups 3 and 4, n = 6) by
intraperitoneal (ip) route. The dosing volume was 10 mL/kg for a
total dose of 10 mg/kg, and dosing formulation was prepared in 1%
(v/v) dimethyl sulfoxide (DMSO)/99% (v/v) 20% (w/v) sulfobutyl
ether-β-cyclodextrin (SBE-β-CD) (Captisol) in water. Food and tap
water was available ad libitum.
For groups 1 and 2 and following ip dosing of each compound,
blood samples were collected from the tail vein into capillary tubes
containing K2EDTA at the following time-points: 0.0833, 0.25, 0.5, 1,
2, 4, 6, 8, and 24 h postdose.
In order to obtain simultaneous blood and brain samples, mice
included in groups 3 and 4 were placed under terminal anesthetic
(isoflurane) and blood samples (0.3 mL) collected from the retro-
orbital sinus into K2EDTA tubes at 0.5 h (n = 3) and 4 h (n = 3) after
intraperitoneal administration of 20r (group 3) and 20g (group 4).
Immediately following blood sample collection death was confirmed
by cervical dislocation and the brain removed.
Aliquots of each blood sample were diluted with an equal volume
of water. Mouse brain samples were weighed, water was added at a 1/
2 w/v ratio (brain/water), and then the samples were homogenized.
Both blood and brain samples were stored in a freezer set to maintain
a temperature of −80 °C until analysis.
Diluted blood and brain homogenates were processed under
standard liquid−liquid extraction procedures using acetonitrile
containing internal standard and analyzed by LC/MS/MS.
Noncompartmental analysis was performed using Phoenix
pharmacokinetic software version 1.4 (Certara), and the main
pharmacokinetic parameters were estimated.
Mouse Efficacy Study of Acute HAT. Six female NMRI mice
(35−40 g weight from Charles River Laboratories) per group were
infected by intraperitoneal (ip) injection with 104 bloodstream forms
of T. b. brucei (STIB795) strain in 0.2 mL of TDB glucose on day 0.
After 3 days, the infected mice were divided into two groups: control
(infected mice treated with vehicle) and 20g (infected mice treated
with 10 mg kg−1 day−1). On day 3, all mice received a 0.2 mL ip
injection with 10 mg kg−1 day−1 20g or 5% DMSO, 20% Captisol for
control group. This treatment was administered for 5 consecutive
days. Parasitemia (measured as parasites per milliliter) was
individually checked by direct microscopic counting of parasites in
a Neubauer chamber using 2 μL of blood from mouse tail, suspending
in 100 μL of TDB glucose. Mortality was checked daily up to 30 days
after infection and expressed as a percentage of cumulative mortality.
Chemistry Experimental. General Methods. All starting
materials were commercially obtained and were used without further
purification, unless specified. Reaction solvents were purified by
passage through alumina columns on a purification system
manufactured by Innovative Technology (Newburyport, MA).
NMR spectra were obtained on Varian NMR systems, operating at
400 or 500 MHz for 1 H acquisitions. LCMS analysis was performed
using a Waters AllianceHT e2795 reverse phase HPLC (Waters
SunFire C18 4.6 mm × 50 mm, 3.5 μm column), with a Waters 2996
photodiode array detector scanning from 210 to 600 nm, and Waters
Micromass ZQ detector (electrospray ionization). Where required,
final compounds were purified by preparative reverse phase HPLC
(columns Waters Symmetry RP8 30 mm × 50 mm, 5 μm column, or
OBD RP18 30 mm × 50 mm, 5 μm), with a single wavelength UV−
visible detector and Waters Micromass ZQ (electrospray ionization).
All final compounds have purities greater than 95% based upon
LCMS analysis. Melting points were obtained on a Thermo Fisher
Mel-Temp apparatus. 1H NMR spectra were obtained with Varian
NMR systems, operating at either 400 or 500 MHz at room
temperature, using solvents from Cambridge Isotope Laboratories.
Chemical shifts (δ, ppm) are reported relative to the solvent peak
(CDCl3, 7.26 [
1H]; DMSO-d6, 2.50 [
1H]; acetone-d6, 2.05; or
CD3OD, 3.31 [
1H]). Data for 1H NMR spectra are reported as
follows: chemical shift (ppm), multiplicity (s for singlet, d for doublet,
t for triplet, dd for doublet of doublet, m for multiplet), coupling
constant (Hz), and integration.
Chemical Synthesis and Characterization. 3-((4-(Pyrazolo-
[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)amino)benzonitrile (1). In
a vial 7a (20 mg, 86 μmol), K3PO4 (26 mg, 121 μmol), XPhos (6 mg,
13 μmol), bis(dibenzylideneacetone)palladium(0) (4 mg, 4.3 μmol),
and 3-aminobenzonitrile (20 mg, 173 μmol) were combined. The vial
was sealed, evacuated, and backfilled with N2 three times. Degassed
and anhydrous toluene (1 mL, dried over molecular sieves and stored
under N2) was added to a sealed vial. The reaction was left stirring
overnight at 101 °C. The reaction mixture which was heterogeneous
was red at room temperature, turned brown and almost clear upon
heating. After 16 h, the reaction mixture was evaporated to dryness to
get a slurry which was extracted with DCM and washed with water
and then dried over sodium sulfate, decanted, and concentrated to get
the crude product which was purified by column chromatography
using EtOAc/hex 40−100% 12 CV to afford the title compound as a
colorless solid (15 mg, 55%). 1H NMR (500 MHz, DMSO-d6) δ ppm
9.96 (s, 1 H), 9.11−9.18 (m, 1 H), 8.93 (s, 1 H), 8.64 (dd, J = 4.4, 2.0
Hz, 1 H), 8.55 (d, J = 5.4 Hz, 1 H), 8.38 (br s, 1 H), 7.93−7.98 (m, 1
H), 7.55 (t, J = 8.1 Hz, 1 H), 7.46−7.51 (m, 2 H), 7.43 (d, J = 7.8 Hz,
1 H). LC−MS (m/z): 314.1 [M + H]+.
3-Chloropyridazine (3). Compound 2 (470 mg, 4.7 mmol) and
POCl3 (4.5 mL, 49 mmol) were heated at 80 °C for 2 h. The
heterogeneous mixture slowly turned clear and then a dark red/brown
color. The reaction mixture was then cooled to room temperature,
poured into water, neutralized slowly with sat. NaHCO3, and
extracted with DCM. The organic layers were washed with water,
brine, dried over sodium sulfate, decanted, and concentrated to afford
the crude compound as a brown solid (360 mg, 64%). 1H NMR (500
MHz, methanol-d4) δ ppm 9.16 (dd, J = 4.9, 1.5 Hz, 1 H), 7.84 (dd, J
= 8.8, 1.5 Hz, 1 H), 7.74 (dd, J = 8.8, 4.9 Hz, 1 H). LC−MS (m/z):
114.4 (35Cl), 116.5 (37Cl) [M + H]+.
4-(Pyridazin-3-yl)morpholine (4a). To a solution of 3 (360 mg,
3.1 mmol) in n-BuOH (5 mL) was added morpholine (0.62 mL, 7.8
mmol). The reaction mixture was heated to 80 °C for 16 h, then
cooled to room temperature. Ethyl acetate was added to the reaction
mixture, and a solid precipitated from solution. The precipitate was
filtered and filtrate was concentrated in vacuo, then purified by column
chromatography using MeOH/EtOAc, 0−20%, 12 CV to afford the
product as a pale-yellow solid (430 mg, 90%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 8.57 (dd, J = 4.4, 1.0 Hz, 1 H), 7.39 (dd, J = 9.3,
4.4 Hz, 1 H), 7.25 (dd, J = 9.3, 1.0 Hz, 1 H), 3.71 (t, J = 4.9 Hz, 4 H),
3.52 (t, J = 4.9 Hz, 4 H). LC−MS (m/z): 165.8 [M + H]+.
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3-Methoxypyridazine (4b). Compound 3 (2.4 g, 21 mmol) was
dissolved in MeOH (150 mL), sodium tert-butoxide (2.01 g, 21
mmol) was added, and the reaction was heated to 65 °C for 16 h. All
volatiles were removed in vacuo and then the reaction mixture was
taken up in EtOAc and MeOH and filtered to give the product in the
filtrate. All volatiles were removed in vacuo to obtain the desired
compound as a red oil (2.30 g, 99%). 1H NMR (500 MHz, DMSO-
d6) δ ppm 8.87 (dd, J = 4.4, 1.5 Hz, 1 H), 7.59 (dd, J = 8.8, 4.4 Hz, 1
H), 7.19 (dd, J = 8.8, 1.5 Hz, 1 H), 4.00 (s, 3 H). LC−MS (m/z):
110.5 [M + H]+.
2-Chloro-4-((trimethylsilyl)ethynyl)pyrimidine (6a). In a vial
5 (500 mg, 3.36 mmol), dichlorobistriphenylphosphine palladium(II)
PdCl2(PPh3)2 (47 mg, 67 μmol), and copper(I) iodide (19 mg, 100
μmol) were added. The vial was evacuated and backfilled with N2
three times. To this, a degassed mixture of triethylamine (1.40 mL,
10.1 mmol) and THF (20 mL) was added followed by
ethynyltrimethylsilane (0.525 mL, 3.69 mmol). The resultant solution
was stirred at 50 °C overnight. The reaction mixture turned from
yellow/orange in color to dark brown after addition of TMS-
acetylene. Upon completion, reaction mixture was concentrated to
give a dark slurry which was extracted with DCM and washed with
water (3 × 50 mL) followed by brine, and the organic layer was dried
using Na2SO4, decanted, and concentrated to give the crude product.
Column purification was performed using EtOAc/hex, 5% to 50% 12
CV, 50−100% 5 CV to afford the product as a white solid (425 mg,
61%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.55 (d, J = 4.9 Hz,
1 H), 7.28 (d, J = 4.9 Hz, 1 H), 0.23 (s, 9 H). LC−MS (m/z): 210.9
(35Cl), 212.9 (37Cl) [M + H]+.
2-Chloro-4-ethynylpyrimidine (6b). A solution of 6a (390 mg,
1.85 mmol) in methanol (10 mL) was treated with half of a stock
solution of KOH (0.519 mg, 9.25 μmol) in 1 mL of MeOH. After 30
min, another half of KOH solution was added and the mixture was
stirred at room temperature; total consumption of the reactant was
observed. The mixture was concentrated to get the crude product as
buff colored solid. Column purification was done using EtOAc/
hexane 10−100%, 15 CV to yield the desired compound as a buff
solid (200 mg, 78%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.64
(d, J = 4.9 Hz, 1 H), 7.37 (d, J = 4.9 Hz, 32 H), 3.48 (s, 1 H). LC−
MS (m/z): 138.6 (35Cl), 140.6 (37Cl) [M + H]+.
2-Chloro-4-((4-(trifluoromethyl)phenyl)ethynyl)pyrimidine
(6c). In a vial 5 (200 mg, 1.34 mmol), dichlorobistriphenylphosphine
palladium(II) PdCl2(PPh3)2 (19 mg, 27 μmol), triethylamine (0.6
mL, 4.03 mmol), and copper(I) iodide (8 mg, 40 μmol) were added
followed by 1-ethynyl-4-(trifluoromethyl)benzene (0.244 mL, 1.48
mmol). A degassed mixture of triethylamine (0.6 mL, 4.03 mmol) and
THF (5 mL) was then added. The resultant solution was stirred at 50
°C overnight. After completion of reaction column purification was
done using EtOAc/hex, 5% to 50% 12 CV, 50−100% 5 CV to isolate
the desired compound as an orange solid (191 mg, 50%). 1H NMR
(500 MHz, DMSO-d6) δ ppm 8.89 (d, J = 5.4 Hz, 1 H), 7.85−7.95
(m, 5 H). LC−MS (m/z): 283.0 (35Cl), 285.0 (37Cl) [M + H]+.
2-Chloro-4-(cyclopropylethynyl)pyrimidine (6d). In a reac-
tion vial 5 (1.0 g, 6.7 mmol), Pd(PPh3)2Cl2 (94 mg, 134 μmol), and
CuI (38 mg, 201 μmol) were added. A degassed solution of
triethylamine (2.81 mL, 20.1 mmol) and THF (12 mL) was added
under N2 to the reaction vial, followed by ethynylcyclopropane (625
μL, 7.38 mmol). The reaction mixture was heated to 50 °C for 16 h.
The reaction mixture was then filtered through Celite and washed
with EtOAc. The reaction mixture was concentrated in vacuo and then
subjected to column purification EtOAc/hexanes 0−25%, to afford
the desired compound as an orange solid (1.03 g, 86%). 1H NMR
(400 MHz, chloroform-d) δ ppm 8.52 (d, J = 5.1 Hz, 1 H), 7.20 (d, J
= 5.1 Hz, 1 H), 1.47−1.56 (m, 1 H), 0.92−1.06 (m, 4 H). LC−MS
(m/z): 178.9 (35Cl), 180.8 (37Cl) [M + H]+.
2-Chloro-4-((4-methoxyphenyl)ethynyl)pyrimidine (6e). In a
vial, 5 (0.3 g, 2.01 mmol), dichlorobistriphenylphosphine palladium-
(II) PdCl2(PPh3)2 (28 mg, 40 μmol), and copper(I) iodide (11.5 mg,
60 μmol) were added, followed by a degassed mixture of
triethylamine (0.84 mL) and THF (5 mL), and then 1-ethynyl-4-
methoxybenzene (293 μL, 2.2 mmol) was added. The resultant
solution was stirred at 50 °C overnight. The yellow/orange reaction
mixture turned dark brown after addition of TMS-acetylene and on
heating. The mixture was evaporated to dryness, and then the slurry
obtained was dissolved in DCM. The organic layer was washed with
water and brine, then dried over sodium sulfate, decanted, and
concentrated to get the crude product which was purified by column
chromatography using EtOAc/hex, 5% to 50% 12 CV, 50−100% 5
CV to afford the title compound as a brown solid (0.4 g, 86%). 1H
NMR (500 MHz, chloroform-d) δ ppm 8.59 (d, J = 5.4 Hz, 1 H),
7.56−7.60 (m, 2 H), 7.36 (d, J = 5.4 Hz, 1 H), 6.91−6.95 (m, 2 H),
3.86 (s, 3 H). LC−MS (m/z): 245.0 (35Cl), 247.0 (37Cl) [M + H]+.
4-(2-Chloropyrimidin-4-yl)-2-methylbut-3-yn-2-ol (6f). In a
reaction vial 5 (2 g, 13.36 mmol), 2-methylbut-3-yn-2-ol (1.56 mL, 16
mmol), Pd(PPh3)2Cl2 (94 mg, 134 μmol), and CuI (51 mg, 269
μmol) were added. A degassed solution of TEA (9.4 mL) and THF
(50 mL) was added under N2 to the reaction vial. The reaction
mixture was heated to 60 °C for 16 h. The reaction was then poured
into water and extracted with DCM. The organic layer was washed
with water and brine, then dried over sodium sulfate, decanted,
concentrated to get the crude product, which was purified by column
chromatography using EtOAc/hex 30−100% 15 CV affording the
desired compound as a yellow solid (1.60 g, 60%). 1H NMR (500
MHz, DMSO-d6) δ ppm 8.78 (d, J = 5.4 Hz, 1 H), 7.61 (d, J = 5.4 Hz,
1 H), 5.79 (s, 1 H), 1.48 (s, 6 H). LC−MS (m/z): 196.9 (35Cl), 198.9
(37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)prop-2-yn-1-ol (6g). In a reaction
vial 5 (1.0 g, 6.7 mmol), Pd(PPh3)2Cl2 (94 mg, 134 μmol), and CuI
(38 mg, 201 μmol) were added. A degassed solution of triethylamine
(3.74 mL, 26.9 mmol) and THF (20 mL) was added under N2 to the
reaction vial, followed by propargyl alcohol (464 μL, 8.06 mmol). The
reaction mixture was heated to 50 °C for 16 h. The reaction was then
filtered through Celite and washed with methanol. The reaction
mixture was concentrated in vacuo, then subjected to column
purification with MeOH/DCM 0−5%, to yield the desired compound
as a brown solid (420 mg, 37%). 1H NMR (500 MHz, DMSO-d6) δ
ppm 8.79 (d, J = 5.4 Hz, 1 H), 7.64 (d, J = 5.4 Hz, 1 H), 5.60 (d, J =
5.9 Hz, 1 H), 4.39 (t, J = 5.9 Hz, 2 H). LC−MS (m/z): 168.8 (35Cl),
170.7 (37Cl) [M + H]+.
2-Chloro-4-(3-methoxyprop-1-yn-1-yl)pyrimidine (6h). In a
reaction vial 5 (500 mg, 3.36 mmol), Pd(PPh3)2Cl2 (47 mg, 67
μmol), and CuI (19 mg, 101 μmol) were added. A degassed solution
of triethylamine (1.87 mL, 13.4 mmol) and THF (10 mL) was added
under N2 to the reaction vial, followed by 3-methoxyprop-1-yne (340
μL, 4.03 mmol). The reaction mixture was heated to 50 °C for 16 h.
The reaction mixture was then filtered through Celite and
concentrated in vacuo and subjected to column purification EtOAc/
hexanes 10−50%, to afford the title compound as a yellow solid (183
mg, 30%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.62 (d, J = 5.4
Hz, 1 H), 7.33 (d, J = 5.4 Hz, 1 H), 4.37 (s, 2 H), 3.47 (s, 3 H). LC−
MS (m/z): 182.8 (35Cl), 184.8 (37Cl) [M + H]+.
4-(2-Chloropyrimidin-4-yl)but-3-yn-2-ol (6i). In a reaction vial
5 (500 mg, 3.4 mmol), Pd(PPh3)2Cl2 (47 mg, 67 μmol), and CuI (19
mg, 100 μmol) were added. A degassed solution of triethylamine (1.9
mL, 13 mmol) and THF (10 mL) was added under N2 to the reaction
vial, followed by but-3-yn-2-ol (320 μL, 4.0 mmol). The reaction
mixture was heated to 50 °C for 16 h. The reaction mixture was then
filtered through Celite and washed with MeOH, then concentrated in
vacuo and subjected to column purification EtOAc/hexanes 20−50%,
to yield the desired compound as a red oil (292 mg, 48%). 1H NMR
(500 MHz, chloroform-d) δ ppm 8.61 (d, J = 4.9 Hz, 1 H), 7.31 (d, J
= 4.9 Hz, 1 H), 4.76−4.85 (m, 1 H), 1.59 (d, J = 6.4 Hz, 3 H). LC−
MS (m/z): 182.9 (35Cl), 184.8 (37Cl) [M + H]+.
2-Chloro-4-(3-methylbut-1-yn-1-yl)pyrimidine (6j). In a
reaction vial 5 (500 mg, 3.36 mmol), Pd(PPh3)2Cl2 (47 mg, 67
μmol), and CuI (19 mg, 101 μmol) were added. A degassed solution
of triethylamine (1.87 mL, 13.4 mmol) and THF (10 mL) was added
under N2 to the reaction vial, followed by 3-methylbut-1-yne (411 μL,
4.03 mmol). The reaction mixture was heated to 50 °C for 16 h. The
reaction mixture was then filtered through Celite and washed with
EtOAc and methanol, then concentrated in vacuo and subjected to
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column purification EtOAc/hexanes 0−25%, to afford the title
compound as a yellow solid (487.1 mg, 80%). 1H NMR (400 MHz,
chloroform-d) δ ppm 8.55 (d, J = 5.1 Hz, 1 H), 7.25 (d, J = 5.1 Hz, 1
H), 2.76−2.94 (m, 1 H), 1.30 (d, J = 7.3 Hz, 6 H). LC−MS (m/z):
180.9 (35Cl), 182.8 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazine (7a).
(Aminooxy)sulfonic acid (906 mg, 8.01 mmol) was dissolved in
water (5 mL). To the clear colorless solution 2.5 M sodium
bicarbonate was added until effervescence ceased (pH ∼ 5). The clear
colorless solution was heated at 70 °C, and pyridazine (0.385 mL,
5.34 mmol) was added, and then the reaction was stirred at 70 °C for
2 h. The reaction mixture then cooled to room temperature,
neutralized with 2.5 M sodium bicarbonate (until effervescence
ceased), and then a solution of 6b (185 mg, 1.34 mmol) in DCM (10
mL) was added followed by KOH (22 mg, 3.9 mmol). Reaction
mixture was stirred overnight at room temperature. After completion
the reaction mixture was extracted in DCM, washed with water and
brine, then dried over sodium sulfate, decanted, and concentrated to
get the crude product. Column purification was performed using
EtOAc/hex 30−100% 15 CV to afford the compound as a red solid
(260 mg, 84%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.04 (s, 1
H), 8.90 (dd, J = 8.8, 2.0 Hz, 1 H), 8.73 (d, J = 5.4 Hz, 1 H), 8.69
(dd, J = 4.4, 2.0 Hz, 1 H), 8.07 (d, J = 5.4 Hz, 1 H), 7.58 (dd, J = 8.8,
4.4 Hz, 1 H). LC−MS (m/z): 231.9 (35Cl), 234.0 (37Cl) [M + H]+.
4-(3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazin-6-yl)-
morpholine (7b). (Aminooxy)sulfonic acid (421 mg, 3.72 mmol)
was dissolved in 3 mL of water, and to the clear solution was added
2.5 M sodium bicarbonate (376 mg, 4.47 mmol) until effervescence
ceased (pH ∼ 5). The clear colorless solution was heated at 70 °C,
and 4a (462 mg, 2.79 mmol) was added and the reaction stirred at 70
°C for 2 h. The reaction mixture was then cooled to room
temperature, neutralized with 2.5 M sodium bicarbonate (until
effervescence ceased). A solution of 6b (129 mg, 931 μmol) in DCM
(10 mL) was added followed by KOH (104 mg, 1.9 mmol), and the
reaction mixture was stirred at room temperature for 16 h. DCM layer
turned dark pink. Reaction mixture was then extracted into DCM, and
the organic layer was washed with water and brine, then dried over
sodium sulfate, decanted, and concentrated to get the crude product,
which was purified by column chromatography using EtOAc/hex,
20−100% 15 CV, to obtain the desired compound as a white solid
(160 mg, 5%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.77 (d, J =
9.8 Hz, 1 H), 8.51 (d, J = 5.4 Hz, 1 H), 8.29 (s, 1 H), 7.45 (d, J = 5.4
Hz, 1 H), 7.03 (d, J = 9.8 Hz, 1 H), 3.88 (t, J = 4.9 Hz, 4 H), 3.62 (t, J
= 4.9 Hz, 4 H). LC−MS (m/z): 317.0 (35Cl), 318.9 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)-6-methoxypyrazolo[1,5-b]-
pyridazine (7c). (Aminooxy)sulfonic acid (1.90 g, 16.8 mmol) was
dissolved in 4 mL of water, and to the clear solution was added
saturated sodium bicarbonate until effervescence ceased (pH ∼ 6).
The clear colorless solution was heated at 70 °C, and 4b (1.24 g, 11.2
mmol) was added in 20 mL of water, and the reaction mixture was
stirred at 70 °C for 2 h. The reaction mixture was then cooled to
room temperature, neutralized with saturated sodium bicarbonate
(until effervescence ceased), and then a solution of 6b (622 mg, 4.49
mmol) in DCM (80 mL) and KOH (252 mg, 4.49 mmol) were
added, and the reaction mixture was stirred at room temperature for
16 h. The reaction mixture was diluted with DCM and water and
extracted. The organic layer was washed with water and brine, then
dried over sodium sulfate, filtered, and evaporated to get the crude
product which was purified by column chromatography using EtOAc/
hex 20−50% to provide the desired product as a brown solid (496 mg,
42%). 1H NMR (500 MHz, DMSO-d6) δ ppm 8.82 (s, 1 H), 8.73 (d,
J = 9.3 Hz, 1 H), 8.70 (d, J = 5.4 Hz, 1 H), 8.01 (d, J = 5.4 Hz, 1 H),
7.27 (d, J = 9.3 Hz, 1 H), 4.02 (s, 3 H). LC−MS (m/z): 262.0 (35Cl),
264.1 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)-2-(4-(trifluoromethyl)phenyl)-
pyrazolo[1,5-b]pyridazine (7d). (Aminooxy)sulfonic acid (559
mg, 4.95 mmol) was dissolved in 5 mL of water, and to the clear
solution was added 2.5 M sodium bicarbonate until effervescence
ceased (pH ∼ 5). The clear colorless solution was heated to 70 °C,
and pyridazine (0.24 mL, 3.30 mmol) was added, and the reaction
mixture was stirred at 70 °C for 2 h. Reaction mixture was cooled to
room temperature, neutralized with 2.5 M sodium bicarbonate (until
effervescence ceased), then solution of 6c (223 mg, 824 μmol) in
DCM (4 mL) and KOH (138 mg, 2.46 mmol) were added, and the
reaction mixture was then stirred overnight at room temperature.
After 16 h the reaction mixture was extracted in DCM, washed the
DCM layer with water, brine and dried over sodium sulfate, decanted,
and concentrated to get the crude product which was purified by
column chromatography using EtOAc/hex, 10−100% 15 CV to afford
the title compound as a bronze solid (150 mg, 47%). 1H NMR (500
MHz, DMSO-d6) δ ppm 8.78 (dd, J = 9.3, 2.0 Hz, 1 H), 8.74 (dd, J =
4.4, 2.0 Hz, 1 H), 8.62 (d, J = 5.4 Hz, 1 H), 7.91 (s, 4 H), 7.60 (dd, J
= 9.3, 4.4 Hz, 1 H), 7.23 (d, J = 5.4 Hz, 1 H). LC−MS (m/z): 314.9
(35Cl), 317.0 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)-2-cyclopropylpyrazolo[1,5-b]-
pyridazine (7e). (Aminooxy)sulfonic acid (1.63 g, 14.4 mmol) was
dissolved in 4 mL of water, and saturated sodium bicarbonate was
added to the clear solution until effervescence ceased (pH ∼ 6). The
clear colorless solution was heated to 70 °C, and pyridazine (693 μL,
9.60 mmol) was added, and the reaction mixture was stirred at 70 °C
for 2 h. The reaction mixture was then cooled to room temperature,
neutralized with saturated sodium bicarbonate (until effervescence
ceased), then a solution of 6d (429 mg, 2.4 mmol) in DCM (7 mL)
was added followed by KOH (135 mg, 2.4 mmol), and the reaction
was stirred for 16 h at room temperature. Partial conversion to
product was observed, so additional KOH (270 mg, 4.8 mmol) was
added. The reaction was stirred for another 8 h. After 8 h another 2
equiv of KOH (270 mg, 4.8 mmol) was added, and the reaction
continued stirring for an additional 16 h. The reaction mixture was
diluted with DCM and washed with water and brine, then dried over
magnesium sulfate, filtered, and evaporated to get the crude product
which was purified by column chromatography using EtOAc/hex 20−
50% and providing the desired compound as a pale-yellow solid
(472.5 mg, 72%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.92
(dd, J = 8.8, 2.0 Hz, 1 H), 8.61 (d, J = 5.4 Hz, 1 H), 8.38 (dd, J = 4.4,
2.0 Hz, 1 H), 7.87 (d, J = 5.4 Hz, 1 H), 7.24 (dd, J = 8.8, 4.4 Hz, 1
H), 2.23−2.31 (m, 1 H), 1.29−1.35 (m, 2 H), 1.17−1.23 (m, 2 H).
LC−MS (m/z): 272.1 (35Cl), 274.1 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)-2-(4-methoxyphenyl)pyrazolo-
[1,5-b]pyridazine (7f). (Aminooxy)sulfonic acid (1.11 g, 9.81
mmol) was dissolved in 5 mL of water, and to the clear solution
2.5 M sodium bicarbonate was added until effervescence ceased (pH
∼ 5). The clear colorless solution was heated to 70 °C, and pyridazine
(0.471 mL, 6.54 mmol) was added, then the reaction mixture was
stirred at 70 °C for 2 h. The reaction cooled to room temperature,
neutralized with 2.5 M sodium bicarbonate (until effervescence
ceased), and then a solution of 6e (0.4 g, 1.63 mmol) in DCM (20
mL) was added followed by KOH (275 mg, 4.9 mmol). The reaction
mixture was stirred at room temperature for 16 h, then diluted with
DCM, washed with water and brine, then dried over sodium sulfate,
decanted, and concentrated to get the crude product, which was
purified by column chromatography using EtOAc/hex, 10−100% 15
CV to provide the title compound as an off-white solid (35 mg, 46%
based on recovered starting material). Recovered 345 mg of unreacted
starting material. 1H NMR (500 MHz, chloroform-d) δ ppm 8.96 (dd,
J = 8.8, 2.0 Hz, 1 H), 8.46 (dd, J = 4.9, 2.0 Hz, 1 H), 8.34 (d, J = 5.4
Hz, 1 H), 7.58−7.61 (m, 2 H), 7.13 (d, J = 5.4 Hz, 1 H), 7.02−7.05
(m, 2 H), 6.89−6.95 (m, 1 H), 3.91 (s, 3 H). LC−MS (m/z): 338.0
(35Cl), 339.9 (37Cl) [M + H]+.
2-(3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazin-2-yl)-
propan-2-ol (7g). (Aminooxy)sulfonic acid (280 mg, 2.47 mmol)
was dissolved in 5 mL of water, and to the clear solution 2.5 M
sodium bicarbonate was added until effervescence ceased (pH ∼ 5).
The clear colorless solution was heated to 70 °C, and pyridazine (119
μL, 1.65 mmol) was added, and the reaction mixture was stirred at 70
°C for 2 h. The reaction was then cooled to room temperature,
neutralized with 2.5 M sodium bicarbonate (until effervescence
ceased), and then a solution of 6f (81 mg, 412 μmol) in DCM (10
mL) was added followed by KOH (69 mg, 1.2 mmol), and the
reaction mixture was stirred at room temperature. After 16 h the
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reaction mixture was diluted with DCM and washed with water and
brine, then dried over sodium sulfate, decanted, and concentrated to
get the crude product which was purified by column chromatography
using EtOAc/hex 30−100% 15 CV to afford the title compound as a
brown solid (47 mg, 40%). 1H NMR (500 MHz, DMSO-d6) δ ppm
8.77 (d, J = 5.4 Hz, 1 H), 8.73 (dd, J = 9.3, 1.5 Hz, 1 H), 8.62 (dd, J =
4.4, 1.5 Hz, 1 H), 8.54 (d, J = 5.4 Hz, 1 H), 7.49 (dd, J = 9.3, 4.4 Hz,
1 H), 5.95 (s, 1 H), 1.64 (s, 6 H). LC−MS (m/z): 290.0 (35Cl), 292.1
(37Cl) [M + H]+.
(3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazin-2-yl)-
methanol (7h). (Aminooxy)sulfonic acid (450 mg, 4.0 mmol) was
dissolved in 3 mL of water, and to the clear solution 2.5 M sodium
bicarbonate was added until effervescence ceased (pH ∼ 5). The clear
colorless solution was heated to 70 °C, and pyridazine (190 μL, 2.7
mmol) was added, and the reaction mixture was stirred at 70 °C for 2
h. The reaction was then cooled to room temperature, neutralized
with 2.5 M sodium bicarbonate (until effervescence ceased), and then
a solution of 6g (110 mg, 670 μmol) in DCM (5 mL) was added
followed by KOH (40 mg, 670 μmol), and the reaction mixture was
stirred at room temperature. After 16 h the reaction mixture was
diluted with DCM and washed with water and brine, then dried over
sodium sulfate. The reaction was filtered and evaporated in vacuo,
then subjected to column purification using MeOH/DCM 2% to
afford the title compound as an orange solid (34 mg, 20%). 1H NMR
(500 MHz, DMSO-d6) δ ppm 8.87 (dd, J = 8.8, 2.0 Hz, 1 H), 8.78 (d,
J = 5.4 Hz, 1 H), 8.67 (dd, J = 4.4, 2.0 Hz, 1 H), 8.05 (d, J = 5.4 Hz, 1
H), 7.56 (dd, J = 8.8, 4.4 Hz, 1 H), 5.76 (t, J = 5.4 Hz, 1 H), 4.89 (d, J
= 5.4 Hz, 1 H). LC−MS (m/z): 262.0 (35Cl), 264.0 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)-2-(methoxymethyl)pyrazolo-
[1,5-b]pyridazine (7i). (Aminooxy)sulfonic acid (680 mg, 6.01
mmol) was dissolved in 5 mL of water, and saturated sodium
bicarbonate was added to the clear solution until effervescence ceased
(pH ∼ 6). The clear colorless solution was heated at 70 °C, and
pyridazine (289 μL, 4.01 mmol) was added, and the reaction was
stirred at 70 °C for 2 h. Reaction mixture was then cooled to room
temperature, neutralized with saturated sodium bicarbonate (until
effervescence ceased), and then a solution of 6h (183 mg, 1.0 mmol)
in DCM (10 mL) was added followed by KOH (112 mg, 2.0 mmol),
and the reaction was stirred for 16 h at room temperature. The
reaction mixture was extracted in DCM washed with water and brine,
then dried over magnesium sulfate, filtered, and evaporated to get the
crude product which was purified by column chromatography using
EtOAc/hex 20−50% to yield the title compound as a white solid (229
mg, 83%). 1H NMR (500 MHz, DMSO-d6) δ ppm 8.86 (dd, J = 9.3,
2.0 Hz, 1 H), 8.79 (d, J = 5.4 Hz, 1 H), 8.69 (dd, J = 4.4, 2.0 Hz, 1
H), 7.85 (d, J = 5.4 Hz, 1 H), 7.57 (dd, J = 9.3, 4.4 Hz, 1 H), 4.86 (s,
2 H), 3.37 (s, 3 H). LC−MS (m/z): 276.0 (35Cl), 278.0 (37Cl) [M +
H]+.
1-(3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazin-2-yl)-
ethan-1-ol (7j). (Aminooxy)sulfonic acid (1.1 g, 9.6 mmol) was
dissolved in 5 mL of water, and saturated sodium bicarbonate was
added to the clear solution until effervescence ceased (pH ∼ 6). The
clear colorless solution was heated at 70 °C, and pyridazine (462 μL,
6.4 mmol) was added, and the reaction mixture was stirred at 70 °C
for 2 h. Reaction mixture was then cooled to room temperature,
neutralized with saturated sodium bicarbonate (until effervescence
ceased), and then a solution of 6i (292 mg, 1.6 mmol) in DCM (15
mL) was added followed by KOH (180 mg, 3.2 mmol), and the
reaction was stirred for 16 h at room temperature. The reaction
mixture was diluted with DCM and washed with water and brine,
then dried over magnesium sulfate, filtered, and evaporated to get the
crude product which was purified by column chromatography using
EtOAc/hex 45−80% to provide the title compound as a yellow solid
(290 mg, 66%). 1H NMR (500 MHz, DMSO-d6) δ ppm 8.81 (d, J =
9.3 Hz, 1 H), 8.76 (d, J = 5.4 Hz, 1 H), 8.63−8.67 (m, 1 H), 8.18 (d, J
= 5.4 Hz, 1 H), 7.52 (dd, J = 9.3, 4.4 Hz, 1 H), 5.76 (d, J = 6.4 Hz, 1
H), 5.25 (quin, J = 6.4 Hz, 1 H), 1.62 (d, J = 6.4 Hz, 3 H). LC−MS
(m/z): 276.0 (35Cl), 278.0 (37Cl) [M + H]+.
3-(2-Chloropyrimidin-4-yl)-2-isopropylpyrazolo[1,5-b]-
pyridazine (7k). (Aminooxy)sulfonic acid (1.83 g, 16.2 mmol) was
dissolved in 5 mL of water, and saturated sodium bicarbonate was
added to the clear solution until effervescence ceased (pH ∼ 6). The
clear colorless solution was heated to 70 °C, and pyridazine (778 μL,
10.8 mmol) was added, and the reaction mixture was stirred at 70 °C
for 2 h. The reaction mixture was then cooled to room temperature,
neutralized with saturated sodium bicarbonate (until effervescence
ceased), and then a solution of 6j (487 mg, 2.7 mmol) in DCM (7
mL) was added followed by KOH (151 mg, 2.70 mmol), and the
reaction was stirred for 16 h at room temperature, at which point
more KOH (302 mg, 5.4 mmol) was added and stirring was
continued for another 3 h. The reaction mixture was diluted with
DCM, washed with water and brine, then dried over magnesium
sulfate, filtered, and evaporated to get the crude product which was
purified by column chromatography using EtOAc/hex 20−50% to
afford the title compound as a yellow solid (471 mg, 64%). 1H NMR
(500 MHz, chloroform-d) δ ppm 8.87 (d, J = 9.3 Hz, 1 H), 8.60 (d, J
= 5.4 Hz, 1 H), 8.39 (d, J = 4.4 Hz, 1 H), 7.47 (d, J = 5.4 Hz, 1 H),
7.24 (dd, J = 9.3, 4.4 Hz, 1 H), 3.54−3.64 (m, 1 H), 1.51 (d, J = 6.4
Hz, 6 H). LC−MS (m/z): 274.1 (35Cl), 276.0 (37Cl) [M + H]+.
(3-(2-Chloropyrimidin-4-yl)-6-methoxypyrazolo[1,5-b]-
pyridazin-2-yl)methanol (7l). (Aminooxy)sulfonic acid (909 mg,
8.0 mmol) was dissolved in 4 mL of water, and saturated sodium
bicarbonate was added to the clear solution until effervescence ceased
(pH ∼ 6). The clear colorless solution was heated at 70 °C, and 4b
(590 mg, 5.36 mmol) was added, then the reaction was stirred at 70
°C for 2 h. The reaction mixture was then cooled to room
temperature, neutralized with saturated sodium bicarbonate (until
effervescence ceased), and then a solution of 6g (452 mg, 2.68 mmol)
in DCM (15 mL) was added followed by KOH (150 mg, 2.7 mmol),
and the reaction mixture was stirred for 16 h at room temperature.
The reaction mixture was diluted with DCM and washed with water
and brine, then dried over sodium sulfate, filtered, and evaporated to
get the crude product which was purified by column chromatography
using EtOAc/hex 25−50% to afford the title compound as an orange
solid (265 mg, 34%). 1H NMR (500 MHz, DMSO-d6) δ ppm 8.76 (d,
J = 5.4 Hz, 1 H), 8.72 (d, J = 9.8 Hz, 1 H), 8.01 (d, J = 5.4 Hz, 1 H),
7.25 (d, J = 9.8 Hz, 1 H), 5.69 (t, J = 5.4 Hz, 1 H), 4.81 (d, J = 5.4 Hz,
2 H), 4.00 (s, 3 H). LC−MS (m/z): 292.0 (35Cl), 294.0 (37Cl) [M +
H]+.
(3-(2-Chloropyrimidin-4-yl)-6-morpholinopyrazolo[1,5-b]-
pyridazin-2-yl)methanol (7m). (Aminooxy)sulfonic acid (590 mg,
5.2 mmol) was dissolved in 5 mL of water, and saturated sodium
bicarbonate was added to the clear solution until effervescence ceased
(pH ∼ 6). The clear colorless solution was heated to 70 °C, and 4a
(570 mg, 3.5 mmol) was added, and the reaction mixture was stirred
at 70 °C for 2 h. Reaction mixture was then cooled to room
temperature, neutralized with saturated sodium bicarbonate (until
effervescence ceased), and then a solution of 6g (290 mg, 5.2 mmol)
in DCM (15 mL) was added followed by KOH (98 mg, 1.7 mmol),
and the reaction mixture was stirred for 16 h at room temperature.
The reaction mixture was diluted with DCM and washed with water
and brine, then dried over sodium sulfate, filtered, and evaporated to
get the crude product which was purified by column chromatography
run isocratically with 100% EtOAc, to afford the title compound as a
yellow solid (88.1 mg, 15%). 1H NMR (500 MHz, DMSO-d6) δ ppm
8.71 (d, J = 5.4 Hz, 1 H), 8.58 (d, J = 9.8 Hz, 1 H), 7.97 (d, J = 5.4
Hz, 1 H), 7.52 (d, J = 9.8 Hz, 1 H), 5.62 (t, J = 5.4 Hz, 1 H), 4.78 (d,
J = 5.4 Hz, 2 H), 3.76 (t, J = 4.9 Hz, 4 H), 3.52 (t, J = 4.9 Hz, 4 H).
LC−MS (m/z): 347.1 (35Cl), 349.0 (37Cl) [M + H]+.
3 - ( 2 - C h l o r o p y r im i d i n - 4 - y l ) - 2 - c y c l o p r o p y l - 6 -
methoxypyrazolo[1,5-b]pyridazine (7n). (Aminooxy)sulfonic
acid (380 mg, 3.36 mmol) was dissolved in 4 mL of water, and to
the clear solution saturated sodium bicarbonate was added until
effervescence ceased (pH ∼ 6). The clear colorless solution was
heated to 70 °C, and 4b (247 mg, 2.24 mmol) was added, and the
reaction mixture was stirred at 70 °C for 2 h. The reaction mixture
was then cooled to room temperature, neutralized with saturated
sodium bicarbonate (until effervescence ceased), and then a solution
of 2-chloro-4-(cyclopropylethynyl)pyrimidine (200 mg, 1.1 mmol) in
DCM (10 mL) was added followed by KOH (63 mg, 1.1 mmol), and
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the reaction was stirred for 16 h at room temperature. Partial
conversion to product was observed, so additional KOH (63 mg, 1.1
mmol) was added, and the reaction was stirred for another 24 h. The
reaction mixture was diluted with DCM and washed with water and
brine, then dried over sodium sulfate, filtered, and evaporated to get
the crude product which was purified by column chromatography
using EtOAc/hex 10−30% to yield the desired compound as a white
solid (99.1 mg, 29%). 1H NMR (500 MHz, DMSO-d6) δ ppm 8.73
(d, J = 5.4 Hz, 1 H), 8.63 (d, J = 9.8 Hz, 1 H), 7.99 (d, J = 5.4 Hz, 1
H), 7.20 (d, J = 9.8 Hz, 1 H), 3.98 (s, 3 H), 2.40−2.46 (m, 1 H),
1.09−1.14 (m, 2 H), 1.00−1.05 (m, 2 H). LC−MS (m/z): 302.1
(35Cl), 304.1 (37Cl) [M + H]+.
4-(3-(2-Chloropyrimidin-4-yl)-2-cyclopropylpyrazolo[1,5-b]-
pyridazin-6-yl)morpholine (7o). (Aminooxy)sulfonic acid (439
mg, 3.89 mmol) was dissolved in 4 mL of water, and saturated sodium
bicarbonate was added to the clear solution until effervescence ceased
(pH ∼ 5). The clear colorless solution was heated to 70 °C, and 4a
(428 mg, 2.59 mmol) was added, and the reaction mixture was stirred
at 70 °C for 2 h. The reaction mixture was then cooled to room
temperature, neutralized with saturated sodium bicarbonate (until
effervescence ceased), and then a solution of 6d (231 mg, 1.3 mmol)
in DCM (20 mL) was added followed by KOH (73 mg, 1.3 mmol),
and the reaction was stirred for 16 h at room temperature. The
reaction mixture was diluted with DCM and washed with water and
brine, then dried over magnesium sulfate, filtered, and evaporated to
get the crude product which was purified by column chromatography
using EtOAc/hex 10−50% to provide the desired compound as a
yellow solid (183.7 mg, 40%). 1H NMR (400 MHz, chloroform-d) δ
ppm 8.71 (d, J = 9.5 Hz, 1 H), 8.55 (d, J = 5.1 Hz, 1 H), 7.84 (d, J =
5.1 Hz, 1 H), 6.98 (d, J = 9.5 Hz, 1 H), 3.86 (t, J = 5.1 Hz, 4 H), 3.58
(t, J = 5.1 Hz, 4 H), 2.13−2.23 (m, 1 H), 1.20−1.28 (m, 2 H), 1.08−
1.18 (m, 2 H). LC−MS (m/z): 357.1 (35Cl), 359.0 (37Cl) [M + H]+.
N-(4-Chlorobenzyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-amine (10a). In a reaction vial 7a (20 mg, 86 μmol)
was stirred in n-BuOH (1 mL), and 4-chlorobenzylamine (25 mg, 170
μmol) was added. The reaction mixture was stirred at 115 °C for 16 h.
The solution changed from a red/brown color to clear yellow on
heating. Upon completion of the reaction, the mixture was
concentrated and taken up in DCM and washed with water and
brine, then dried over sodium sulfate, decanted, and concentrated to
get the crude product, which was purified by column chromatography
using EtOAc/hexane 20−100%, 12 CV to yield the product as a
colorless solid (7 mg, 24%). 1H NMR (500 MHz, chloroform-d) δ
ppm 8.46 (s, 1 H), 8.35 (dd, J = 4.2, 1.7 Hz, 1 H), 8.31 (d, J = 5.4 Hz,
1 H), 7.30−7.41 (m, 4 H), 6.99−7.07 (m, 1 H), 6.94 (d, J = 5.4 Hz, 1
H), 5.54−5.68 (m, 1 H), 4.70 (d, J = 5.9 Hz, 2 H). LC−MS (m/z):
337.0 (35Cl), 339.1 (37Cl) [M + H]+.
N-(3-Morpholinopropyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-amine (10b). In a microwave vial containing 7a (30
mg, 129 μmol), EtOH (1 mL) was added followed by 3-
morpholinopropan-1-amine (37 mg, 260 μmol), and the reaction
mixture was subjected to microwave irradiation at 150 °C for 15 min.
Upon completion of the reaction, the reaction mixture was
concentrated and taken up in DCM which was washed with water
and brine, then dried over sodium sulfate, decanted, and concentrated
to get the crude product, which was purified by column
chromatography using EtOAc/MeOH 0−20%, 12 CV to yield the
product as a dark yellow solid (15 mg, 34%). 1H NMR (500 MHz,
chloroform-d) δ ppm 8.97 (dd, J = 9.3, 2.0 Hz, 1 H), 8.45 (s, 1 H),
8.37 (dd, J = 4.4, 2.0 Hz, 1 H), 8.27 (d, J = 4.9 Hz, 1 H), 7.16 (dd, J =
9.3, 4.4 Hz, 1 H), 6.86 (d, J = 4.9 Hz, 1 H), 6.01 (br s, 1 H), 3.79 (t, J
= 4.2 Hz, 4 H), 3.59 (q, J = 6.3 Hz, 2 H), 2.57−2.65 (m, 6 H), 1.91
(quin, J = 6.4 Hz, 2 H). LC−MS (m/z): 340.1 [M + H]+.
N-Cyclopropyl-4-(6-morpholinopyrazolo[1,5-b]pyridazin-3-
yl)pyrimidin-2-amine (10d). In a vial 7b (15 mg, 47 μmol) and
cyclopropylamine (1.0 mL, 14 mmol) were stirred in 1 mL of n-
BuOH. Reaction mixture was subjected to microwave irradiation at
150 °C for 1 h. The reaction mixture was then evaporated to dryness
and column purification performed using EtOAc/hex 50−100% 12
CV followed by EtOAc/MeOH 1−20% 5 CV to afford the title
compound as a brown solid (8.9 mg, 55%). 1H NMR (500 MHz,
chloroform-d) δ ppm 8.83−8.91 (m, 1 H), 8.28 (d, J = 4.9 Hz, 1 H),
8.23 (s, 1 H), 6.92 (d, J = 9.3 Hz, 1 H), 6.90 (d, J = 4.9 Hz, 1 H), 5.38
(br s, 1 H), 3.87 (t, J = 4.9 Hz, 4 H), 3.59 (t, J = 4.9 Hz, 4 H), 2.82−
2.87 (m, 1 H), 0.85−0.90 (m, 2 H), 0.62−0.66 (m, 2 H). LC−MS
(m/z): 338.1 [M + H]+.
N-Phenyl-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
amine (10e). An oven-dried flask containing 7a (10 mg, 43 μmol) in
DMSO (0.1 mL) was heated until the solution became clear, then n-
BuOH (0.3 mL) and aniline (8 μL, 86 μmol) were added to the flask.
The reaction mixture was heated to 120 °C for 16 h. After completion
of reaction, the mixture was evaporated to dryness and column
purification was performed using EtOAc/hex 20−100% 15 CV to
obtain the product as an orange solid (10 mg, 80%). Mp = 207−209
°C. 1H NMR (500 MHz, chloroform-d) δ ppm 8.91 (dd, J = 9.3, 2.0
Hz, 1 H), 8.52 (s, 1 H), 8.43 (d, J = 5.4 Hz, 1 H), 8.40 (dd, J = 4.4,
2.0 Hz, 1 H), 7.61−7.65 (m, 2 H), 7.37−7.43 (m, 2 H), 7.18 (br s, 1
H), 7.11−7.16 (m, 2 H), 7.08 (d, J = 5.37 Hz, 1 H). LC−MS (m/z):
289.3 [M + H]+.
N-Phenyl-4-(2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-amine (10f). To an oven-dried flask
containing a solution of 7d (20 mg, 53 μmol) in n-BuOH (1 mL),
aniline (10 μL, 106 μmol) was added, and the reaction was heated to
110 °C for 16 h. After completion of reaction, reaction mixture was
evaporated to dryness and column purification was performed using
EtOAc/hex, 20−100% 12 CV to afford the title compound as a
colorless solid (20 mg, 87%). 1H NMR (500 MHz, chloroform-d) δ
ppm 8.69 (dd, J = 9.3, 2.0 Hz, 1 H), 8.43 (dd, J = 4.4, 2.0 Hz, 1 H),
8.26 (d, J = 5.4 Hz, 1 H), 7.87 (d, J = 8.3 Hz, 2 H), 7.74 (d, J = 8.3
Hz, 2 H), 7.59−7.62 (m, 2 H), 7.33−7.37 (m, 2 H), 7.09−7.16 (m, 2
H), 6.60 (d, J = 5.4 Hz, 1 H). LC−MS (m/z): 433.1 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)-N-(o-tolyl)pyrimidin-2-
amine (10g). To an oven-dried flask containing o-toluidine (19 μL,
173 μmol) and 7a (20 mg, 86 μmol), n-BuOH was added. The
reaction mixture was heated at 100 °C for 16 h. After completion of
reaction, the mixture was evaporated to dryness and column
purification was performed using EtOAc/hex 20−100% 15 CV to
yield the title compound as an off-white solid (7 mg, 27%). Mp =
177−178 °C. 1H NMR (500 MHz, chloroform-d) δ ppm 8.64 (dd, J =
9.3, 2.0 Hz, 1 H), 8.49 (s, 1 H), 8.40 (d, J = 5.4 Hz, 1 H), 8.35 (dd, J
= 4.4, 2.0 Hz, 1 H), 7.82 (d, J = 7.8 Hz, 1 H), 7.28−7.32 (m, 2 H),
7.16 (td, J = 7.3, 1.5 Hz, 1 H), 7.01−7.05 (m, 2 H), 6.86 (br s, 1 H),
2.36 (s, 3 H). LC−MS (m/z): 303.3 [M + H]+.
N-(3-Nitrophenyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-amine (10h). In a vial 7a (50 mg, 216 μmol) and 3-
nitroaniline (52 mg, 540 μmol) were stirred in n-BuOH (1.5 mL),
and the reaction mixture was subjected to microwave irradiation at
150 °C for 2 h. After completion of reaction, the mixture was filtered
and washed with MeOH. The precipitate was purified using column
chromatography using EtOAc/hex, 50−100%, to yield the title
compound as a yellow solid (52 mg, 72%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 10.14 (s, 1 H), 9.15−9.21 (m, 1 H), 8.98 (s, 1 H),
8.92 (t, J = 2.4 Hz, 1 H), 8.66 (dd, J = 4.4, 2.0 Hz, 1 H), 8.59 (d, J =
5.4 Hz, 1 H), 8.11 (dd, J = 8.3, 2.0 Hz, 1 H), 7.84 (dd, J = 8.3, 2.0 Hz,
1 H), 7.64 (t, J = 8.3 Hz, 1 H), 7.53 (d, J = 5.4 Hz, 1 H), 7.49 (dd, J =
8.8, 4.4 Hz, 1 H). LC−MS (m/z): 334.0 [M + H]+.
N-(3-Methoxyphenyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-amine (10i). To an oven-dried flask containing 3-
methoxyaniline (22 μL, 194 μmol), a solution of 7a (30 mg, 130
μmol) and acetic acid (1 mL) in dioxane (2 mL) was added. The
reaction mixture was stirred at 110 °C for 23 h and monitored by
TLC. The reaction mixture appeared dark red/brown, and some solid
particles were observed. Upon completion, the mixture was extracted
with DCM (3 × 100 mL). The combined organic phase was washed
with brine and dried over sodium sulfate. Column purification was
performed by preparative reverse phase HPLC using 5−100% ACN/
water system to afford the pure product as white solid (15 mg, 36%).
1H NMR (500 MHz, DMSO-d6) δ ppm 9.57 (s, 1 H), 9.17−9.24 (m,
1 H), 8.90 (s, 1 H), 8.62 (dd, J = 4.4, 2.0 Hz, 1 H), 8.49 (d, J = 5.4
Hz, 1 H), 7.43−7.49 (m, 2 H), 7.39 (d, J = 5.4 Hz, 1 H), 7.33 (d, J =
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8.3 Hz, 1 H), 7.23 (t, J = 8.3 Hz, 1 H), 6.58 (dd, J = 7.8, 2.4 Hz, 1 H),
3.76 (s, 3 H). LC−MS (m/z): 319.0 [M + H]+.
4-(2-Cyclopropylpyrazolo[1,5-b]pyridazin-3-yl)-N-(3,4-
difluorophenyl)pyrimidin-2-amine (10n). In a vial, 7e (30 mg,
110 μmol) and 3,4-difluoroaniline (21 mg, 170 μmol) were dissolved
in n-BuOH (1.5 mL). The vial was sealed, and the reaction was
subjected to microwave irradiation at 150 °C for 2 h. The reaction
was cooled to room temperature, then filtered and washed with
diethyl ether. The precipitate was taken up in DCM and washed with
saturated sodium bicarbonate. The organic layer was dried over
sodium sulfate, filtered, and evaporated in vacuo to yield the product
(22 mg, 55%). 1H NMR (400 MHz, chloroform-d) δ ppm 8.66 (dd, J
= 8.8, 1.5 Hz, 1 H), 8.48 (d, J = 5.1 Hz, 1 H), 8.32 (dd, J = 4.4, 1.5
Hz, 1 H), 7.86 (dd, J = 8.1, 2.2 Hz, 1 H), 7.36 (d, J = 5.1 Hz, 1 H),
7.09−7.15 (m, 3 H), 2.32−2.42 (m, 1 H), 1.29−1.35 (m, 2 H), 1.13−
1.21 (m, 2 H). LC−MS (m/z): 365.0 [M + H]+.
N-(4-(tert-Butyl)phenyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-amine (10s). To an oven-dried flask was added 4-
tertbutylaniline (28 μL, 173 μmol) to a solution of 7a (20 mg, 86
μmol) in n-BuOH. The reaction mixture was heated to 100 °C for 16
h. After completion of reaction, the mixture was evaporated to dryness
and column purification was performed using EtOAc/hex 20−100%
15 CV to afford the title compound as a yellow solid (16 mg, 53%).
1H NMR (500 MHz, chloroform-d) δ ppm 8.83 (dd, J = 8.8, 2.0 Hz, 1
H), 8.51 (s, 1 H), 8.39 (dd, J = 4.4, 2.0 Hz, 1 H), 8.36 (d, J = 5.4 Hz,
1 H), 7.70 (br s, 1 H), 7.49−7.54 (m, 2 H), 7.40−7.45 (m, 2 H), 7.09
(dd, J = 8.8, 4.4 Hz, 1 H), 7.05 (d, J = 5.4 Hz, 1 H), 1.37 (s, 9 H).
LC−MS (m/z): 345.4 [M + H]+.
3-(2-Chloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine (11).
(Aminooxy)sulfonic acid (490 mg, 4.33 mmol) was dissolved in 2
mL of water, and to the clear solution was added 2.5 M sodium
bicarbonate until effervescence ceased (pH ∼ 5). The clear colorless
solution was heated to 70 °C, and pyridine (0.233 mL, 2.89 mmol)
was added, and the reaction mixture was stirred at 70 °C for 2 h. The
reaction was cooled to room temperature, neutralized with 2.5 M
sodium bicarbonate (until effervescence ceased), and then solution of
6b (185 mg, 1.34 mmol) in DCM (10 mL) was added followed by
KOH (100 mg, 1.78 mmol). The reaction was stirred for 16 h at room
temperature. The reaction mixture was then diluted with DCM and
washed with water and brine, then dried over sodium sulfate,
decanted, and concentrated to get the crude product, which was
purified by column chromatography using EtOAc/hex, 50−100% 12
CV, followed by EtOAc/MeOH 0−20% 5 CV to obtain the desired
compound as a beige solid (85 mg, 51%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 8.95 (s, 1 H), 8.90 (d, J = 6.8 Hz, 1 H), 8.62 (d, J =
5.4 Hz, 1 H), 8.49 (d, J = 8.8 Hz, 1 H), 7.97 (d, J = 5.4 Hz, 1 H),
7.62−7.68 (m, 1 H), 7.19 (td, J = 6.8, 1.5 Hz, 1 H). LC−MS (m/z):
230.9 (35Cl), 232.9 (37Cl) [M + H]+.
N-Cyclopropyl-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-
amine (12a). In a vial 11 (10 mg, 43 μmol), cyclopropylamine (6 μL,
87 μmol), and DIPEA (16 μL, 87 μmol) were stirred in n-BuOH and
subjected to microwave irradiation at 150 °C for 1 h. The reaction
mixture was evaporated to dryness and purified by column
chromatography using EtOAc/hex, 40−100%, 7 CV, followed by
MeOH/EtOAc, 0−20% 5 CV to yield the title compound as a
colorless solid (8 mg, 66%). 1H NMR (500 MHz, chloroform-d) δ
ppm 8.69−8.79 (m, 1 H), 8.52 (d, J = 6.8 Hz, 1 H), 8.42 (s, 1 H),
8.28 (d, J = 4.9 Hz, 1 H), 7.33 (ddd, J = 8.8, 6.8, 1.0 Hz, 1 H), 6.87−
6.95 (m, 2 H), 2.82−2.92 (m, 1 H), 0.84−0.93 (m, 2 H), 0.60−0.68
(m, 2 H). LC−MS (m/z): 252.0 [M + H]+.
N-Phenyl-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine
(12b). In a vial were added 11 (10 mg, 43 μmol) and aniline (8 μL,
87 mmol), and the mixture was stirred in n-BuOH at 110 °C for 16 h.
The reaction mixture was evaporated to dryness and purified by
column chromatography using EtOAc/hex, 40−100% 12 CV followed
by EtOAc/MeOH 1−20% 5 CV to afford the title compound as a
beige solid (11 mg, 88%). 1H NMR (500 MHz, chloroform-d) δ ppm
8.51−8.57 (m, 2 H), 8.46 (s, 1 H), 8.35−8.40 (m, 1 H), 7.67 (d, J =
7.3 Hz, 2 H), 7.36−7.41 (m, 2 H), 7.28−7.35 (m, 2 H), 7.10 (t, J =
7.3 Hz, 1 H), 7.04 (d, J = 5.4 Hz, 1 H), 6.89−6.95 (m, 1 H). LC−MS
(m/z): 288.0 [M + H]+.
N-(3-Methoxyphenyl)-4-(pyrazolo[1,5-a]pyridin-3-yl)-
pyrimidin-2-amine (12c). In a vial 11 (20 mg, 87 μmol) and 3-
anisidine (20 μL, 0.173 mmol) were stirred in n-BuOH at 110 °C for
16 h. The reaction mixture was then evaporated to dryness and
column purification was performed using EtOAc/hex 40−100% 12
CV followed by EtOAc/MeOH 1−20% 5 CV to afford the title
compound as a beige solid (11 mg, 40%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 9.49 (s, 1 H), 8.81−8.86 (m, 2 H), 8.77 (d, J = 8.8
Hz, 1 H), 8.41 (d, J = 5.4 Hz, 1 H), 7.46−7.52 (m, 2 H), 7.30−7.37
(m, 2 H), 7.22 (t, J = 8.1 Hz, 1 H), 7.11 (t, J = 6.8 Hz, 1 H), 6.57 (dd,
J = 8.3, 2.2 Hz, 1 H), 3.76 (s, 3 H). LC−MS (m/z): 318.0 [M + H]+.
3-((4-(Pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-
benzonitrile (12d). In a vial 11 (20 mg, 87 μmol), K3PO4 (37 mg,
173 μmol), XPhos (6 mg, 13 μmol), tris(dibenzylideneacetone)-
palladium(0) (4.0 mg, 4.3 μmol), and 3-aminobenzonitrile (20.5 mg,
173 μmol) were added. The vial was evacuated, then backfilled with
N2 three times. Degassed anhydrous toluene (1 mL) was added to a
sealed vial. The reaction mixture was degassed for another 5 min and
left stirring at 110 °C for 16 h. The heterogeneous red reaction
mixture slowly turned yellow and clear with some floating particles.
The reaction mixture was evaporated to dryness and purified by using
preparative reverse phase HPLC to afford the title compound as a
pale-yellow solid (6 mg, 22%). 1H NMR (500 MHz, chloroform-d) δ
ppm 9.19 (s, 1 H), 8.86 (d, J = 7.0 Hz, 1 H), 8.85 (s, 1 H), 8.71 (d, J
= 9.0 Hz, 1 H), 8.53 (s, 1 H), 8.48 (d, J = 5.0 Hz, 1 H), 8.43 (t, J =
2.0 Hz, 1 H), 7.96 (dt, J = 8.0, 1.5 Hz, 1 H), 7.56−7.52 (m, 2 H),
7.42−7.41 (m, 2 H), 7.13 (td, J = 7.0, 1.5 Hz, 1 H). LC−MS (m/z):
313.0 [M + H]+.
Methyl Pyrazolo[1,5-b]pyridazine-3-carboxylate (14a).
(Aminooxy)sulfonic acid (8.1 g, 71 mmol) was dissolved in 13 mL
of water, and to the clear colorless solution was added saturated
sodium bicarbonate until effervescence ceased (pH ∼ 6). The clear
colorless solution was heated to 70 °C, and pyridazine (3.4 mL, 48
mmol) was added dropwise, and the reaction was stirred at 70 °C for
2 h. The reaction was cooled to room temperature, neutralized with
sat. sodium bicarbonate (until effervescence ceased), and then a
solution of 13 (1.1 mL, 12 mmol) in DCM (50 mL) was added
followed by KOH (1.3 g, 24 mmol). The reaction was stirred for 16 h
at room temperature. After completion of reaction, the reaction
mixture was diluted with DCM, washed with water, brine, and dried
over magnesium sulfate, filtered, and evaporated to obtain the desired
compound as a tan solid (1.5 g, 71%). 1H NMR (500 MHz,
chloroform-d) δ ppm 8.56 (dd, J = 9.0, 1.7 Hz, 1 H), 8.49 (s, 1 H),
8.44 (dd, J = 4.2, 1.7 Hz, 1 H), 7.25−7.29 (m, 1 H), 3.94 (s, 3 H).
LC−MS (m/z): 177.9 [M + H]+.
Pyrazolo[1,5-b]pyridazine-3-carboxylic Acid Hydrochloride
(14b). In a round-bottom flask 14a (1.0 g, 5.6 mmol) was dissolved in
water (15 mL), sodium hydroxide (677 mg, 16.9 mmol) was added,
and the reaction was heated to 70 °C for 1 h. The reaction was cooled
to room temperature, and 1 M HCl was added, which caused a
precipitate to form. The precipitate was filtered to yield the desired
product as a white solid (414 mg, 37%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 8.62 (dd, J = 4.4, 2.0 Hz, 1 H), 8.52 (dd, J = 9.3,
2.0 Hz, 1 H), 8.47 (s, 1 H), 7.48 (dd, J = 9.3, 4.4 Hz, 1 H). LC−MS
(m/z): 163.8 [M + H]+.
3-Bromopyrazolo[1,5-bpyridazine (15). In a round-bottom
flask 14b (410 mg, 2.1 mmol) was dissolved in anhydrous DMF (10
mL), N-bromosuccinimide (520 mg, 2.9 mmol) was added, and the
reaction was stirred at room temperature for 3 h. The reaction was
poured into water and extracted with EtOAc, then the organic layer
was washed three times with 1 M LiCl, followed by brine, then dried
over magnesium sulfate, filtered, and evaporated in vacuo to yield the
compound as a white solid (327 mg, 80%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 8.51 (dd, J = 4.4, 2.0 Hz, 1 H), 8.27 (s, 1 H), 8.19
(dd, J = 8.8, 2.0 Hz, 1 H), 7.30 (dd, J = 8.8, 4.4 Hz, 1 H). LC−MS
(m/z): 197.8 (79Br), 199.8 (81Br) [M + H]+.
3-Phenylpyrazolo[1,5-b]pyridazine (16a). In a vial 15 (42.1
mg, 213 μmol) was added to 1.5 mL of 3:1 mixture of degassed
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dioxane/water, 0.25 mL of DCM was added followed by phenyl
boronic acid (31.1 mg, 255 μmol), Pd(dppf)2Cl2 (9 mg, 11 μmol),
and potassium carbonate (88 mg, 628 μmol). The reaction mixture
was subjected to microwave irradiation and heated to 130 °C for 1 h.
The reaction was diluted with DCM and water and extracted 3 times
into DCM, washed with brine, dried over magnesium sulfate, filtered,
and evaporated in vacuo. Column purification was performed using
EtOAc/hex 0−50% to afford the product as a white solid (6.2 mg,
15%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.31 (dd, J = 4.4,
2.0 Hz, 1 H), 8.24 (s, 1 H), 8.21 (dd, J = 8.8, 2.0 Hz, 1 H), 7.56−7.60
(m, 2 H), 7.47−7.51 (m, 2 H), 7.34−7.38 (m, 1 H), 7.05 (dd, J = 8.8,
4.4 Hz, 1 H). LC−MS (m/z): 196.0 [M + H]+.
3-(3-Chlorophenyl)pyrazolo[1,5-b]pyridazine (16b). In a
sealed vial 15 (100 mg, 505 μmol), 28 (103 mg, 656 μmol),
potassium acetate (209 mg, 1.51 mmol), and PdCl2(dppf)·CH2Cl2
(21 mg, 25 mmol) were stirred in 4 mL of 3:1 mixture of degassed
dioxane/water. The reaction was evacuated and backfilled with N2
three times, then subjected to microwave irradiation at 130 °C for 1 h.
The reaction was cooled and filtered through Celite and washed with
EtOAc, then concentrated in vacuo. Column purification was
performed using EtOAc/hex 25−50% to yield the desired compound
as a yellow solid (83 mg, 72%). 1H NMR (500 MHz, chloroform-d) δ
ppm 8.34 (dd, J = 4.4, 2.0 Hz, 1 H), 8.23 (s, 1 H), 8.19 (dd, J = 9.3,
2.0 Hz, 1 H), 7.55−7.57 (m, 1 H), 7.44−7.48 (m, 1 H), 7.41 (t, J =
7.8 Hz, 1 H), 7.31−7.35 (m, 1 H), 7.09 (dd, J = 9.3, 4.4 Hz, 1 H).
LC−MS (m/z): 230.2 (35Cl), 232.0 (37Cl) [M + H]+.
3-((3-(Pyrazolo[1,5-b]pyridazin-3-yl)phenyl)amino)-
benzonitrile (17). In a sealed vial 16b, 3-aminobenzonitrile (51 mg,
435 μmol), cesium carbonate (212 mg, 653 μmol), palladium(II)
acetate (2.4 mg, 10.9 μmol), and Xantphos (12.6 mg, 21.7 μmol)
were stirred in anhydrous dioxane (2 mL), and the reaction mixture
was evacuated and backfilled with N2 three times. The reaction
mixture was then subjected to microwave irradiation at 160 °C for 1
h. The reaction was filtered through Celite and washed with EtOAc,
then evaporated to dryness. Column purification was performed using
EtOAc/hex 20−50%, to afford the title compound as a yellow solid
(31.9 mg, 47%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.32 (dd,
J = 4.4, 2.0 Hz, 1 H), 8.21 (s, 1 H), 8.18 (dd, J = 8.8, 2.0 Hz, 1 H),
7.43 (t, J = 7.8 Hz, 1 H), 7.33−7.38 (m, 2 H), 7.27−7.29 (m, 2 H),
7.24−7.25 (m, 1 H), 7.17−7.21 (m, 1 H), 7.10 (dd, J = 7.8, 2.0 Hz, 1
H), 7.07 (dd, J = 8.8, 4.4 Hz, 1 H), 5.94 (br s, 1 H). LC−MS (m/z):
312.1 [M + H]+.
3-(Pyridin-2-yl)pyrazolo[1,5-b]pyridazine (18a). In a vial,
(aminooxy)sulfonic acid (658 mg, 5.82 mmol) was dissolved in 1
mL of water, and to the clear colorless solution saturated sodium
bicarbonate was added until effervescence ceased (pH ∼ 6). The clear
colorless solution was heated to 70 °C, and pyridazine (0.280 mL,
3.88 mmol) was added dropwise, and the reaction was stirred at 70
°C for 2 h. Reaction mixture then cooled to room temperature,
neutralized with saturated sodium bicarbonate (until effervescence
ceased), and then a solution of 2-ethynylpyridine (100 mg, 0.716
μmol) in DCM (8 mL) was added followed by 1,8-
diazabicyclo[5.4.0]undec-7-ene (0.145 mL, 970 μmol). The reaction
mixture was subjected to microwave irradiation at 100 °C for 30 min,
then 120 °C for 30 min. The reaction was then left stirring at 40 °C
for 72 h After completion, the reaction mixture was extracted in
DCM, washed with water, brine, and dried over sodium sulfate,
filtered, and evaporated to get the crude product. Column purification
was performed using EtOAc/hex 20−50%, followed by a second
column purification using MeOH/DCM 0−5% to afford the title
compound as an orange solid (7.1 mg, 4%). 1H NMR (500 MHz,
chloroform-d) δ ppm 9.03 (dd, J = 9.3, 2.0 Hz, 1 H), 8.65−8.69 (m, 1
H), 8.47 (s, 1 H), 8.37 (dd, J = 4.4, 2.0 Hz, 1 H), 7.76 (td, J = 7.3, 2.0
Hz, 1 H), 7.68−7.72 (m, 1 H), 7.18 (ddd, J = 7.3, 4.9, 1.0 Hz, 1 H),
7.15 (dd, J = 9.3, 4.4 Hz, 1 H). LC−MS (m/z): 196.9 [M + H]+.
3-((6-(Pyrazolo[1,5-b]pyridazin-3-yl)pyridin-2-yl)amino)-
benzonitrile (18b). In a sealed vial 29 (27.5 mg, 119 μmol), cesium
carbonate (117 mg, 358 μmol), 3-aminobenzonitrile (28 mg, 238
μmol), palladium(II) acetate (1.3 mg, 6.0 μmol), and Xantphos (6.9
mg, 11.9 μmol) were stirred in anhydrous dioxane (1.5 mL), the
reaction mixture was evacuated and backfilled with N2 three times.
The reaction mixture was then subjected to MW irradiation at 160 °C
for 1 h. The reaction was filtered through Celite and washed with
EtOAc, then evaporated to dryness. Column purification was
performed using EtOAc/hex 20−50% to afford the product as a
yellow solid (16.0 mg, 43%). 1H NMR (500 MHz, chloroform-d) δ
ppm 8.84 (dd, J = 9.3, 2.0 Hz, 1 H), 8.45 (s, 1 H), 8.36 (dd, J = 4.4,
2.0 Hz, 1 H), 8.09 (s, 1 H), 7.65 (t, J = 7.8 Hz, 1 H), 7.52−7.57 (m, 1
H), 7.44 (t, J = 7.8 Hz, 1 H), 7.32−7.36 (m, 1 H), 7.15 (dd, J = 9.3,
4.4 Hz, 1 H), 6.66 (d, J = 7.8 Hz, 1 H), 6.54−6.60 (m, 1 H). LC−MS
(m/z): 313.1 [M + H]+.
3-(Pyridin-4-yl)pyrazolo[1,5-b]pyridazine (18c). (Aminooxy)-
sulfonic acid (486 mg, 4.30 mmol) was dissolved in 2 mL of water, to
the clear colorless solution saturated sodium bicarbonate was added
until effervescence ceased (pH ∼ 6). The clear colorless solution was
heated to 70 °C, and pyridazine (0.207 mL, 2.87 mmol) was added
dropwise, then the reaction was stirred at 70 °C for 2 h. The reaction
mixture was then cooled to room temperature, and neutralized with
saturated sodium bicarbonate (until effervescence ceased), then a
solution of 4-ethynylpyridine HCl (100 mg, 0.716 μmol) in DCM (5
mL) was added followed by KOH (40 mg, 716 μmol). The reaction
mixture was stirred at room temperature for 16 h. After completion of
reaction the reaction mixture was diluted with DCM, washed with
water, brine and dried over sodium sulfate, filtered, and evaporated to
get the crude product. Column purification was performed using
EtOAc/hex 50−100% to yield the product as an off-white solid (16
mg, 11%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.68 (dd, J =
4.4, 2.0 Hz, 2 H), 8.39 (dd, J = 4.4, 2.0 Hz, 1 H), 8.35 (s, 1 H), 8.27
(dd, J = 9.3, 2.0 Hz, 1 H), 7.50 (dd, J = 4.4, 2.0 Hz, 2 H), 7.17 (dd, J
= 9.3, 4.4 Hz, 1 H). LC−MS (m/z): 196.9 [M + H]+.
3-((4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyridin-2-yl)amino)-
benzonitrile (18d). In a vial 30 (50 mg, 217 μmol), cesium
carbonate (212 mg, 650 μmol), palladium(II) acetate (2.43 mg, 11
μmol), Xantphos (12.5 mg, 22 μmol), and 3-aminobenzonitrile (25.6
mg, 217 μmol) were added followed by anhydrous dioxane (1.5 mL)
and the vial was sealed. The reaction mixture was evacuated and
backfilled with N2 three times. The reaction mixture was then
subjected to microwave irradiation at 160 °C for 1 h, then filtered
through Celite and washed with EtOAc, and evaporated to dryness.
Column purification was performed using MeOH/DCM 2−10%
followed by reverse phase column purification using ACN/water 5−
95% with 0.1% formic acid, to afford the title compound as a yellow
solid (6.6 mg, 10%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.39
(dd, J = 4.4, 2.0 Hz, 1 H), 8.30−8.36 (m, 2 H), 8.24 (dd, J = 8.8, 2.0
Hz, 1 H), 7.99−8.04 (s, 1 H), 7.64 (d, J = 7.8 Hz, 1 H), 7.43 (t, J =
7.8 Hz, 1 H), 7.31 (d, J = 7.8 Hz, 1 H), 7.17 (dd, J = 8.8, 4.4 Hz, 1
H), 7.07 (d, J = 5.4 Hz, 1 H), 6.98 (s, 1 H), 6.84 (br s, 1 H). LC−MS
(m/z): 313.1 [M + H]+.
3-((4-Methyl-6-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
yl)amino)benzonitrile (19a). In a vial 26 (30 mg, 122 μmol) and 3-
aminobenzonitrile (29 mg, 244 μmol) were stirred in n-BuOH (1.5
mL) and subjected to microwave irradiation at 150 °C for 2 h.
Reaction was filtered and washed with diethyl ether, the precipitate
was taken up in DCM and washed with a saturated sodium
bicarbonate solution and brine, then dried over magnesium sulfate,
filtered, and evaporated in vacuo, to yield the product as a white solid
(19.8 mg, 50%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.89 (s, 1
H), 9.05−9.11 (m, 1 H), 8.87 (s, 1 H), 8.61 (dd, J = 4.4, 2.0 Hz, 1
H), 8.34−8.37 (m, 1 H), 7.97 (d, J = 7.8 Hz, 1 H), 7.53 (t, J = 7.8 Hz,
1 H), 7.45 (dd, J = 9.3, 4.4 Hz, 1 H), 7.38−7.42 (m, 2 H), 2.43 (s, 3
H). LC−MS (m/z): 328.2 [M + H]+.
3-((5-Methyl-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
yl)amino)benzonitrile (19b). In a vial 29 (35 mg, 140 μmol), 3-
aminobenzonitrile (34 mg, 430 μmol), cesium carbonate (139 mg,
427 μmol), palladium(II) acetate (1.6 mg, 7.1 μmol), and Xantphos
(8.2 mg, 14 μmol) were stirred in 1.5 mL of anhydrous dioxane. The
reaction mixture was sealed and then evacuated and backfilled with N2
three times. The reaction mixture was then subjected to microwave
irradiation at 130 °C for 1 h. The reaction was filtered through Celite
and washed with EtOAc, then evaporated to dryness. Column
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purification was performed using MeOH/DCM 0−5%, followed by
another column purification using MeOH/DCM 1−3% to afford the
title compound as a white solid (7.4 mg, 16%). 1H NMR (500 MHz,
DMSO-d6) δ ppm 9.87 (s, 1 H), 9.11 (dd, J = 9.3, 2.0 Hz, 1 H), 8.71
(s, 1 H), 8.66 (dd, J = 4.4, 2.0 Hz, 1 H), 8.46−8.49 (m, 1 H), 8.36 (t,
J = 2.0 Hz, 1 H), 7.93−7.98 (m, 1 H), 7.51 (t, J = 7.8 Hz, 1 H), 7.46
(dd, J = 9.3, 4.4 Hz, 1 H), 7.36−7.40 (m, 1 H), 2.46 (s, 3 H). LC−
MS (m/z): 328.1 [M + H]+.
3-((4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)oxy)-
benzonitrile (20a). 3-Hydroxybenzonitrile (8 mg, 65 μmol) in
anhydrous DMF was stirred with potassium carbonate (13 mg, 97
μmol) at room temperature under N2 for 30 min, then 7a (15 mg, 65
μmol) was added and the reaction mixture was stirred at 80 °C for 16
h. After completion of reaction, the reaction mixture was dumped in
water and extracted with EtOAc. Organic layer was then washed with
water, brine and dried over sodium sulfate, decanted and concentrated
to get the crude product which was purified by column
chromatography using acetone/hex 20−50% 15 CV then 50−100%
5 CV to afford the title compound as a white solid (11 mg, 51%). 1H
NMR (500 MHz, chloroform-d) δ ppm 8.56 (d, J = 5.4 Hz, 1 H),
8.54 (s, 1 H), 8.39−8.45 (m, 2 H), 7.59−7.66 (m, 3 H), 7.53−7.57
(m, 1 H), 7.40 (d, J = 5.4 Hz, 1 H), 7.11 (dd, J = 8.8, 4.4 Hz, 1 H).
LC−MS (m/z): 315.0 [M + H]+.
3-(Methyl(4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)-
amino)benzonitrile (20b). In a vial 7a (100 mg, 430 μmol), cesium
carbonate (420 mg, 1.3 mmol), 3-(methylamino)benzonitrile (110
mg, 860 μmol), palladium(II) acetate (4.8 mg, 22 μmol), and
Xantphos (27 mg, 43 μmol) were added in 5 mL of anhydrous
dioxane. The reaction mixture was sealed then evacuated and
backfilled with N2 three times. The reaction mixture was then
subjected to microwave irradiation at 160 °C for 1 h. The reaction
was filtered through Celite and washed with EtOAc, then evaporated
to dryness. Column purification was done using MeOH/DCM 0−4%,
followed by isocratic column purification 80% EtOAc/hexanes
affording the title compound as an off-white solid (18.8 mg, 13%).
1H NMR (500 MHz, DMSO-d6) δ ppm 8.88 (s, 1 H), 8.58 (dd, J =
4.4, 2.0 Hz, 1 H), 8.45 (d, J = 5.4 Hz, 1 H), 8.38 (dd, J = 9.3, 2.0 Hz,
1 H), 8.00 (s, 1 H), 7.83 (d, J = 7.8 Hz, 1 H), 7.75 (d, J = 7.8 Hz, 1
H), 7.66 (t, J = 7.8 Hz, 1 H), 7.38 (d, J = 5.4 Hz, 1 H), 7.30 (dd, J =
9.3, 4.4 Hz, 1 H), 3.59 (s, 3 H). LC−MS (m/z): 328.2 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)-N-(3-(trifluoromethyl)-
phenyl)pyrimidin-2-amine (20c). In a vial 7a (50 mg, 216 μmol),
3-(trifluoromethyl)aniline (67 μL, 540 μmol) were stirred in n-BuOH
(1.5 mL), and the reaction mixture was subjected to microwave
irradiation at 150 °C for 2 h. After completion the reaction was
evaporated to dryness and column purification was performed using
EtOAc/hex, 33−66% to afford the title compound as a white solid (52
mg, 68%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.95 (s, 1 H),
9.10−9.18 (m, 1 H), 8.93 (s, 1 H), 8.64 (dd, J = 4.4, 2.0 Hz, 1 H),
8.55 (d, J = 5.4 Hz, 1 H), 8.30 (s, 1 H), 7.97 (d, J = 8.3 Hz, 1 H), 7.57
(t, J = 8.3 Hz, 1 H), 7.43−7.50 (m, 2 H), 7.33 (d, J = 8.3 Hz, 1 H).
LC−MS (m/z): 357.0 [M + H]+.
2-Fluoro-3-((4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
yl)amino)benzonitrile (20d). In a vial 3-(2-chloropyrimidin-4-
yl)pyrazolo[1,5-b]pyridazine 7a (40 mg, 173 μmol), cesium carbonate
(169 mg, 518 μmol), 3-amino-2-fluorobenzonitrile (47 mg, 345
μmol), palladium(II) acetate (2 mg, 8.6 μmol), and Xantphos (10 mg,
17 μmol) were added in anhydrous dioxane (1.5 mL), the reaction
mixture was sealed then evacuated and backfilled with N2 three times.
The reaction mixture was then subjected to microwave irradiation at
160 °C for 1 h. The reaction was filtered through Celite and washed
with EtOAc, then evaporated to dryness. The reaction mixture was
taken up in DCM and water, and extracted 2X into DCM, then
washed with brine, dried with Na2SO4, filtered, and evaporated in
vacuo. Column purification was performed using EtOAc/hex 25−
100% followed by reverse phase column purification using ACN/
water 5−95% with 0.1% ammonium hydroxide, to afford the title
compound as a white solid (5.0 mg, 9%). 1H NMR (400 MHz,
DMSO-d6) δ ppm 9.62 (s, 1 H), 8.94−9.01 (m, 1 H), 8.90 (s, 1 H),
8.56−8.63 (m, 1 H), 8.45 (d, J = 5.1 Hz, 1 H), 8.19 (t, J = 7.3 Hz, 1
H), 7.65 (t, J = 7.3 Hz, 1 H), 7.43 (s, 3 H). LC−MS 332.0 (m/z): [M
+ H]+.
4-Fluoro-3-((4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
yl)amino)benzonitrile (20e). In a vial 7a (40 mg, 173 μmol),
cesium carbonate (169 mg, 518 μmol), 3-amino-4-fluorobenzonitrile
(47 mg, 345 μmol), palladium(II) acetate (2 mg, 8.6 μmol), and
Xantphos (10 mg, 17 μmol) were added with anhydrous dioxane (1.5
mL), the reaction mixture was sealed, then evacuated and backfilled
with N2 three times. The reaction mixture was then subjected to
microwave irradiation at 160 °C for 1 h. The reaction was filtered
through Celite and washed with EtOAc, then evaporated to dryness.
Column purification was done using EtOAc/hex 25−100%, followed
by MeOH/DCM 4% with 5% ammonium hydroxide, followed by
reverse phase column purification using ACN/water 5−95% with
0.1% ammonium hydroxide, to afford the title compound as a white
solid (5.0 mg, 8.7%). 1H NMR (400 MHz, DMSO-d6) δ ppm 9.60 (s,
1 H), 9.11 (d, J = 8.8 Hz, 1 H), 8.93 (s, 1 H), 8.63 (dd, J = 4.4, 2.2
Hz, 1 H), 8.49−8.58 (m, 2 H), 7.62−7.67 (m, 1 H), 7.49−7.59 (m, 2
H), 7.43 (dd, J = 8.8, 4.4 Hz, 1 H). LC−MS (m/z): 332.0 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)-N-(pyridin-2-yl)pyrimidin-
2-amine (20f). In a vial 7a (40 mg, 173 μmol), cesium carbonate
(169 mg, 518 μmol), 2-aminopyridine (33 mg, 350 μmol),
palladium(II) acetate (2 mg, 8.6 μmol), and Xantphos (10 mg, 17
μmol) were added to anhydrous dioxane (1.5 mL), the reaction
mixture was sealed then evacuated and backfilled with N2 three times.
The reaction mixture was then subjected to microwave irradiation at
160 °C for 1 h. The reaction was filtered through Celite and washed
with EtOAc, then evaporated to dryness. Column purification was
performed using EtOAc/hex 50−100%, to afford the title compound
as a pale-yellow solid (20.2 mg, 41%).1H NMR (400 MHz,
chloroform-d) δ ppm 9.00 (dd, J = 8.8, 2.2 Hz, 1 H), 8.54 (s, 1
H), 8.51 (d, J = 5.1 Hz, 1 H), 8.43 (dd, J = 4.4, 2.2 Hz, 1 H), 8.40 (d,
J = 8.1 Hz, 1 H), 8.34 (d, J = 5.1 Hz, 1 H), 7.96 (br s, 1 H), 7.69−
7.76 (m, 1 H), 7.22 (dd, J = 8.8, 4.4 Hz, 1 H), 7.16 (d, J = 5.1 Hz, 1
H), 6.98 (dd, J = 8.1, 5.1 Hz, 1 H). LC−MS (m/z): 290.1 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)-N-(pyridin-3-yl)pyrimidin-
2-amine (20g). In a vial 7a (50 mg, 216 μmol), cesium carbonate
(140 mg, 431 μmol), palladium(II) acetate (0.9 mg, 4 μmol), and
Xantphos (4 mg, 7 μmol) were dissolved in 2 mL of anhydrous
dioxane, the reaction mixture was sealed then evacuated and backfilled
with N2 three times. The reaction mixture was then subjected to
microwave irradiation at 160 °C for 1 h. The reaction was filtered
through Celite and washed with EtOAc, then concentrated in vacuo.
Reverse phase preparative HPLC purification was performed using
ACN/water 5−95% with 0.1% formic acid, to afford the title
compound as a white solid (9.1 mg, 15%), isolated as a 0.5 eq formic
acid solvate. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.79 (s, 1 H),
9.12−9.18 (m, 1 H), 8.92 (s, 1 H), 8.89 (d, J = 2.0 Hz, 1 H), 8.63
(dd, J = 4.4, 2.0 Hz, 1 H), 8.51 (d, J = 5.4 Hz, 1 H), 8.41 (br s, 1 H),
8.24 (d, J = 8.3 Hz, 1 H), 8.20 (d, J = 4.9 Hz, 1 H), 7.48 (dd, J = 8.8,
4.4 Hz, 1 H), 7.44 (d, J = 5.4 Hz, 1 H), 7.37 (dd, J = 8.3, 4.9 Hz, 1
H). LC−MS (m/z): 290.2 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)-N-(pyridin-4-yl)pyrimidin-
2-amine (20h). In a vial 7a (30 mg, 130 μmol) and 4-aminopyridine
(18 mg, 190 μmol) were stirred in n-BuOH (1.5 mL) and heated to
150 °C for 2 h. The reaction was concentrated in vacuo. Column
purification was performed using EtOAc/hexanes 50−75% then
changed to MeOH/DCM 0−20%, a second column was run using an
isocratic method MeOH/DCM 30%, to afford the title compound as
a yellow solid (5.2 mg, 14%). 1H NMR (400 MHz, methanol-d4) δ
ppm 9.39 (d, J = 7.3 Hz, 2 H), 9.05 (d, J = 9.5 Hz, 1 H), 8.93 (s, 1
H), 8.85 (d, J = 5.1 Hz, 1 H), 8.61 (d, J = 4.4 Hz, 1 H), 8.03 (d, J =
5.1 Hz, 1 H), 7.55 (dd, J = 9.5, 4.4 Hz, 1 H), 7.09 (d, J = 7.3 Hz, 2
H). LC−MS (m/z): 290.1 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)-N-(pyrimidin-5-yl)-
pyrimidin-2-amine (20i). In a vial 7a (50 mg, 220 μmol), 5-
aminopyrimidine (205 mg, 2.2 mmol), palladium(II) acetate (2.4 mg,
11 μmol), Xantphos (12.5 mg, 21.6 μmol), and cesium carbonate
(211 mg, 648 μmol) were stirred in anhydrous dioxane (5 mL). The
reaction mixture was sealed then evacuated and backfilled with N2
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three times. The reaction was then subjected to microwave irradiation
at 160 °C for 1.5 h. The reaction was filtered through Celite and
washed with EtOAc, then evaporated to dryness. Column purification
was performed using MeOH/DCM 0−5%, followed by reverse phase
preparative HPLC column purification using ACN/water 5−70% with
0.1% formic acid, to afford the title compound as a white solid (3.6
mg, 6%). 1H NMR (500 MHz, chloroform-d) δ ppm 9.14 (s, 2 H),
8.97 (s, 1 H), 8.85 (dd, J = 8.8, 2.0 Hz, 1 H), 8.56 (s, 1 H), 8.50 (d, J
= 5.4 Hz, 1 H), 8.44 (dd, J = 4.9, 2.0 Hz, 1 H), 7.25 (dd, J = 8.8, 4.4
Hz, 1 H), 7.20 (d, J = 5.4 Hz, 1 H), 7.05 (br s, 1 H). LC−MS (m/z):
291.2 [M + H]+.
N-(4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)-
pyridazin-4-amine (20j). In a vial 7a (50 mg, 216 μmol) and 4-
aminopyridazine (41 mg, 432 μmol) were stirred in n-BuOH (1.5
mL) and subject to microwave irradiation to 120 °C for 30 min. The
reaction was concentrated in vacuo and column purification was
performed MeOH/DCM 2−20% followed by reverse phase
preparative HPLC purification using ACN/water 5−50% with 0.1%
formic acid, to afford the title compound as a yellow solid (5.5 mg,
11%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.21−9.26 (m, 1 H),
9.13 (dd, J = 8.78, 2.0 Hz, 1 H), 9.10 (s, 1 H), 8.87 (d, J = 5.4 Hz, 1
H), 8.69 (dd, J = 4.4, 2.0 Hz, 1 H), 8.35−8.41 (m, 2 H), 8.05 (d, J =
5.4 Hz, 1 H), 7.58 (dd, J = 8.8, 4.4 Hz, 1 H), 6.84−6.89 (m, 1 H).
LC−MS (m/z): 291.1 [M + H]+.
N-(6-Methylpyridin-3-yl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-amine (20k). In a vial 7a (50 mg, 220 μmol), 3-amino-
6-methylpyridine (47 mg, 430 μmol), cesium carbonate (211 mg, 648
μmol), palladium(II) acetate (2.4 mg, 11 μmol), and Xantphos (12.5
mg, 21.6 μmol) were stirred in anhydrous dioxane (1.5 mL). The
reaction mixture was sealed then evacuated and backfilled with N2
three times. The reaction mixture was then subjected to microwave
irradiation at 160 °C for 1 h. The reaction was filtered through Celite
and washed with EtOAc, then evaporated to dryness. Reverse phase
preparative HPLC column purification was performed using ACN/
water 5−70% with 0.1% formic acid. The compound was then taken
up in DCM and stirred with resin-bound silicon carbonate for 12 h
then filtered and evaporated in vacuo, to afford the title compound as
an off-white solid (25.9 mg, 40%). 1H NMR (500 MHz, DMSO-d6) δ
ppm 9.64 (s, 1 H), 9.09−9.16 (m, 1 H), 8.90 (s, 1 H), 8.73 (d, J = 2.4
Hz, 1 H), 8.62 (dd, J = 4.4, 2.0 Hz, 1 H), 8.48 (d, J = 5.4 Hz, 1 H),
8.11 (dd, J = 8.8, 2.4 Hz, 1 H), 7.47 (dd, J = 8.8, 4.4 Hz, 1 H), 7.40
(d, J = 5.4 Hz, 1 H), 7.22 (d, J = 8.8 Hz, 1 H), 2.44 (s, 3 H). LC−MS
(m/z): 304.2 [M + H]+.
3-((4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)amino)-
propan-1-ol (20l). To an oven-dried flask 3-aminopropan-1-ol (7
mg, 90 μmol) and 7a (10 mg, 43 μmol) were added in n-BuOH. The
reaction mixture was stirred at 110 °C for 16 h. After completion of
reaction mixture was evaporated to dryness and the solid obtained
was titrated with cold methanol, filtered and dried under high vacuum
affording the title compound as a solid (6 mg, 68%). 1H NMR (400
MHz, DMSO-d6) δ ppm 9.01−9.25 (m, 1 H), 8.82 (s, 1 H), 8.58 (d, J
= 5.1 Hz, 1 H), 8.27 (d, J = 4.4 Hz, 1 H), 7.41 (dd, J = 8.8, 4.4 Hz, 1
H), 7.19 (br s, 1 H), 7.10 (d, J = 5.1 Hz, 1 H), 4.53 (br s, 1 H), 3.37−
3.60 (m, 4 H), 1.64−1.82 (m, 2 H). LC−MS (m/z): 271.1 [M + H]+.
N-(4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)-
acrylamide (20m). To the solution of (10 mg, 47 μmol, prepared by
refluxing 3-(2-chloropyrimidin-4-yl)pyrazolo[1,5-b]pyridazine in liq
NH3, added triethylamine (10 μL, 71 μmol) in 1 mL THF followed
by acryloyl chloride (6 μL, 71 μmol), and reaction mixture was stirred
at 50 °C overnight. The reaction mixture then evaporated to dryness
and taken up in DCM, washed with water and brine then dried over
sodium sulfate, decanted, and concentrated to get the crude product
which was purified by column chromatography using EtOAc/hex 30−
100% 12 CV to afford the title compound as a solid (6 mg, 48%). 1H
NMR (400 MHz, DMSO-d6) δ ppm 10.93 (s, 1 H), 9.71 (d, J = 8.8
Hz, 1 H), 8.97 (s, 1 H), 8.57−8.70 (m, 2 H), 7.71 (d, J = 5.1 Hz, 1
H), 7.53 (dd, J = 8.8, 4.4 Hz, 1 H), 6.71 (dd, J = 16.9, 10.3 Hz, 1 H),
6.40 (d, J = 16.9 Hz, 1 H), 5.85 (d, J = 10.3 Hz, 1 H). LC−MS (m/
z): 267.1 [M + H]+.
4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-amine (20n).
In a vial 10a (34.3 mg, 103 μmol) was dissolved in TFA (2 mL)
and stirred at 80 °C for 20 min. The reaction was quenched with
saturated sodium bicarbonate and filtered. The precipitate was
purified using column purification using MeOH/DCM 5% to afford
the title compound as a white solid (8.1 mg, 37%). 1H NMR (400
MHz, chloroform-d) δ ppm 8.99 (d, J = 8.8 Hz, 1 H), 8.49 (s, 1 H),
8.41 (d, J = 4.4 Hz, 1 H), 8.32 (d, J = 5.1 Hz, 1 H), 7.20 (dd, J = 8.8,
4.4 Hz, 1 H), 6.99 (d, J = 5.1 Hz, 1 H), 5.02 (br s, 2 H). LC−MS (m/
z): 213.0 [M + H]+.
N-Methyl-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
amine (20o). In a vial 7a (30 mg, 130 μmol) and methylamine (2.0
M solution in THF) (129.5 μL, 259 μmol) were stirred in n-BuOH
and subjected to microwave irradiation at 150 °C for 2 h. The
reaction was concentrated in vacuo, then subjected to column
purification using EtOAc/hexanes 50−100% to afford the title
compound as an off-white solid (22.8 mg, 78%). 1H NMR (400
MHz, methanol-d4) δ ppm 9.12 (dd, J = 8.8, 2.2 Hz, 1 H), 8.65 (s, 1
H), 8.49 (dd, J = 4.4, 2.2 Hz, 1 H), 8.22 (d, J = 5.1 Hz, 1 H), 7.36
(dd, J = 8.8, 4.4 Hz, 1 H), 7.07 (d, J = 5.1 Hz, 1 H), 3.02 (s, 3 H).
LC−MS (m/z): 227.0 [M + H]+.
N-Isopropyl-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
amine (20p). In a vial 7a (50 mg, 220 μmol) and isopropylamine (35
μL, 430 μmol) were stirred in n-BuOH (1.5 mL), and the reaction
mixture was subjected to microwave irradiation at 150 °C for 2 h.
After completion of reaction mixture was evaporated to dryness.
Column purification performed using reverse phase preparative
HPLC using 5−35% ACN/water system, affording the title
compound as a yellow solid (7.0 mg, 15%). 1H NMR (500 MHz,
methanol-d4) δ ppm 9.00−9.13 (m, 1 H), 8.88 (s, 1 H), 8.64 (dd, J =
4.4, 2.0 Hz, 1 H), 8.16 (d, J = 6.4 Hz, 1 H), 7.57 (dd, J = 8.8, 4.4 Hz,
1 H), 7.38 (d, J = 6.4 Hz, 1 H), 4.89−4.90 (m, 1 H), 1.40 (d, J = 6.35
Hz, 6 H). LC−MS (m/z): 255.1 [M + H]+.
N-Cyclohexyl-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
amine (20q). In a vial 7a (50 mg, 216 μmol) and cyclohexylamine
(49 μL, 432 μmol) were stirred in 1.5 mL of n-BuOH, and the
reaction was subjected to microwave irradiation at 150 °C for 2 h, the
reaction was then conventionally heated to 50 °C for 12 h, and then
subjected to microwave irradiation at 150 °C for 30 min. The reaction
was filtered and washed with diethyl ether to give the crude product in
the precipitate. Reverse phase preparative HPLC purification was
performed using ACN/water 5−95% with 0.1% formic acid to afford
the title compound as a white solid (26.2 mg, 41%). 1H NMR (500
MHz, chloroform-d) δ ppm 8.96 (dd, J = 8.8, 2.0 Hz, 1 H), 8.46 (s, 1
H), 8.38 (dd, J = 4.4, 2.0 Hz, 1 H), 8.23−8.32 (m, 1 H), 7.16 (dd, J =
8.8, 4.5 Hz, 1 H), 6.86 (d, J = 5.4 Hz, 1 H), 5.12 (br s, 1 H), 3.84−
3.95 (m, 1 H), 2.09−2.19 (m, 2 H), 1.76−1.87 (m, 2 H), 1.64−1.73
(m, 1 H), 1.41−1.53 (m, 2 H), 1.22−1.38 (m, 3 H). LC−MS (m/z):
295.1 [M + H]+.
4-((4-(Pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-yl)amino)-
cyclohexan-1-ol (20r). In a vial 7a (0.040 g, 173 μmol), 4-
aminocyclohexanol (0.040 g, 347 μmol) were stirred in n-BuOH (1.5
mL), and the reaction mixture was subjected to microwave irradiation
at 150 °C for 2 h. After completion of reaction mixture was filtered
and washed with diethyl ether, the filtrate was evaporated to dryness
and column purification was performed using MeOH/DCM 2−4% to
yield the title compound as a white solid (6.0 mg, 11%). 1H NMR
(500 MHz, methanol-d4) δ ppm 9.04−9.13 (m, 1 H), 8.64 (s, 1 H),
8.49 (dd, J = 4.4, 2.0 Hz, 1 H), 8.21 (d, J = 5.4 Hz, 1 H), 7.36 (dd, J =
8.8, 4.4 Hz, 1 H), 7.04 (d, J = 5.4 Hz, 1 H), 3.76−3.87 (m, 1 H),
3.58−3.67 (m, 1 H), 2.09−2.20 (m, 2 H), 1.98−2.08 (m, 2 H), 1.35−
1.53 (m, 4 H). LC−MS (m/z): 311.1 [M + H]+.
3-((4-(2-(4-Methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)benzonitrile (21a). In a vial were added 7f
(20 mg, 59 μmol), anhydrous K3PO4 (25 mg, 118 μmol), XPhos (4
mg, 9 μmol), tris(dibenzylideneacetone)palladium(0) (3 mg, 3.0
μmol), and 3-aminobenzonitrile (14 mg, 118 μmol). The vial was
sealed with a stir bar and evacuated and backfilled with N2 three
times. Degassed anhydrous toluene (1 mL, dried over molecular
sieves and stored under N2) was added to a sealed vial and the
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reaction mixture was degassed with nitrogen for an additional 5 min.
The reaction was stirred at 101 °C for 16 h. The reaction mixture was
evaporated to dryness and then extracted with DCM and washed with
water, and brine then dried over sodium sulfate, decanted and
concentrated to get the crude product. Purification was done by
column chromatography using EtOAc/hex 40−100% 12 CV to yield
the title compound as a yellow solid (3 mg, 12%). 1H NMR (500
MHz, chloroform-d) δ ppm 8.71 (dd, J = 9.0, 1.5 Hz, 1 H), 8.40 (dd, J
= 4.5, 2.0 Hz, 1 H), 8.31 (s, 1 H), 8.27 (d, J = 5.0 Hz, 1 H), 7.66 (d, J
= 8.0 Hz, 1 H), 7.63 (d, J = 9.0 Hz, 2 H), 7.414 (t, J = 8.0 Hz, 1 H),
7.36−7.32 (m, 2 H), 7.20 (dd, J = 9.0, 4.5 Hz, 1 H), 7.00 (d, J = 9.0
Hz, 2 H), 6.76 (d, J = 5.5 Hz, 1 H), 3.89 (s, 3 H). LC−MS (m/z):
420.0 [M + H]+.
3-((4-(2-(4-(Trifluoromethyl)phenyl)pyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-yl)amino)benzonitrile (21b). In a
vial 7d (15 mg, 40 μmol), cesium carbonate (39 mg, 120 μmol), 3-
aminobenzonitrile (9 mg, 80 μmol), palladium(II) acetate (0.5 mg,
4.0 μmol), and Xantphos (2.3 mg, 4 μmol) were added in 1.5 mL of
anhydrous dioxane. The reaction mixture was sealed then evacuated
and backfilled with N2 three times. The reaction mixture was then
subjected to microwave irradiation at 160 °C for 1 h. The reaction
was filtered through Celite and washed with EtOAc, then evaporated
to dryness. Column purification was performed using EtOAc/hexanes
25−100%, to yield the title compound as a pale-yellow solid (11.7 mg,
64%). 1H NMR (500 MHz, DMSO-d6) δ ppm 10.06 (s, 1 H), 8.80−
8.85 (m, 1 H), 8.69 (dd, J = 4.4, 2.0 Hz, 1 H), 8.50 (d, J = 5.4 Hz, 1
H), 8.19 (s, 1 H), 7.89 (d, J = 8.3 Hz, 2 H), 7.82−7.87 (m, 3 H), 7.49
(dd, J = 8.8, 4.4 Hz, 1 H), 7.41 (t, J = 7.8 Hz, 1 H), 7.36 (d, J = 7.8
Hz, 1 H), 6.79 (d, J = 5.37 Hz, 1 H). LC−MS (m/z): 458.1 [M +
H]+.
3-((4-(2-(2-Hydroxypropan-2-yl)pyrazolo[1,5-b]pyridazin-3-
yl)pyrimidin-2-yl)amino)benzonitrile (21c). In a vial 7g (71 mg,
170 μmol), and 3-aminobenzonitrile (87 mg, 740 μmol) were stirred
in n-BuOH (2 mL) and the reaction mixture was subjected to
microwave irradiation at 150 °C for 2 h. After completion of reaction
mixture was evaporated to dryness and column purification was done
using MeOH/DCM 0−5%, followed by column purification 25−
100% EtOAc/hexanes, followed by preparative reverse phase HPLC
purification 30−100% ACN/water, affording the title compound as a
white solid (2.9 mg, 4%). 1H NMR (500 MHz, methanol-d4) δ ppm
8.54−8.60 (m, 2 H), 8.47 (dd, J = 4.4, 1.5 Hz, 1 H), 8.26 (s, 1 H),
7.89 (d, J = 8.3 Hz, 1 H), 7.51 (d, J = 5.4 Hz, 1 H), 7.47 (t, J = 8.3 Hz,
1 H), 7.31−7.38 (m, 2 H), 1.69 (s, 6 H). LC−MS (m/z): 372.1 [M +
H]+.
3-((4-(2-(Hydroxymethyl)pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)benzonitrile (21d). In a vial 7h (33.5 mg,
128 μmol) and 3-aminobenzonitrile (37.8 mg, 320 μmol) were stirred
in n-BuOH (2 mL) and subjected to microwave irradiation at 150 °C
for 1 h. The reaction mixture was filtered, and the precipitate was
washed with MeOH. The precipitate was found to contain the desired
product as a brown solid (8 mg, 18%). 1H NMR (500 MHz, DMSO-
d6) δ ppm 9.96 (s, 1 H), 9.02−9.09 (m, 1 H), 8.58−8.64 (m, 2 H),
8.38 (s, 1 H), 7.96 (dd, J = 8.3, 2.0 Hz, 1 H), 7.49−7.56 (m, 2 H),
7.40−7.47 (m, 2 H), 5.64 (br s, 1 H), 4.87 (s, 2 H). LC−MS (m/z):
344.2 [M + H]+.
3-((4-(2-(Methoxymethyl)pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)benzonitrile (21e). In a vial were added 7i
(100 mg, 362 μmol) and 3-aminobenzonitrile (85.7 mg, 725 μmol)
with 1.5 mL of n-BuOH. The reaction mixture was subjected to
microwave irradiation at 150 °C for 2 h. The reaction was cooled to
room temperature, filtered, and washed with diethyl ether to yield the
desired product in the precipitate as an off-white solid (116.8 mg,
90%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.98 (s, 1 H), 9.03−
9.09 (m, 1 H), 8.65 (dd, J = 4.4, 2.0 Hz, 1 H), 8.62 (d, J = 5.4 Hz, 1
H), 8.38 (s, 1 H), 7.94−7.99 (m, 1 H), 7.53 (t, J = 8.1 Hz, 1 H), 7.46
(dd, J = 8.8, 4.4 Hz, 1 H), 7.42 (d, J = 7.3 Hz, 1 H), 7.33 (d, J = 5.4
Hz, 1 H), 4.84 (s, 2 H), 3.37 (s, 3 H). LC−MS (m/z): 358.1 [M +
H]+.
3-((4-(2-(1-Hydroxyethyl)pyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)benzonitrile (21f). In a vial were added 7j
(100 mg, 363 μmol) and 3-aminobenzonitrile (86 mg, 725 μmol)
with 1.5 mL of n-BuOH. The reaction mixture was subjected to
microwave irradiation at 150 °C for 2 h. The reaction was then
concentrated in vacuo. Column purification was performed using
EtOAc/hex 45−100% to afford the title compound as a white solid
(95.5 mg, 74%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.96 (s, 1
H), 8.93 (d, J = 8.8 Hz, 1 H), 8.58−8.63 (m, 2 H), 8.38 (s, 1 H), 7.97
(d, J = 8.3 Hz, 1 H), 7.59 (d, J = 5.4 Hz, 1 H), 7.51 (t, J = 8.3 Hz, 1
H), 7.39−7.44 (m, 2 H), 5.63 (d, J = 6.4 Hz, 1 H), 5.28 (quin, J = 6.4
Hz, 1 H), 1.62 (d, J = 6.4 Hz, 3 H). LC−MS (m/z): 358.1 [M + H]+.
3-((4-(2-Isopropylpyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-
2-yl)amino)benzonitrile (21g). In a vial 7k (100 mg, 365 μmol)
and 3-aminobenzonitrile (86 mg, 731 μmol) were stirred in 1.5 mL of
n-BuOH. The reaction mixture was subjected to microwave
irradiation and heated to 150 °C for 2 h. The reaction mixture was
concentrated in vacuo. Column purification was performed using 1−
5% MeOH in DCM, followed by reverse phase preparative HPLC
purification using ACN/water 5−95% with 0.1% formic acid,
providing the title compound as a tan solid (36.8 mg, 28%). 1H
NMR (500 MHz, DMSO-d6) δ ppm 9.98 (s, 1 H), 8.75−8.82 (m, 1
H), 8.59 (d, J = 5.4 Hz, 1 H), 8.55 (d, J = 4.4 Hz, 1 H), 8.37 (s, 1 H),
7.97 (d, J = 8.3 Hz, 1 H), 7.51 (t, J = 8.3 Hz, 1 H), 7.37−7.43 (m, 2
H), 7.20 (d, J = 5.4 Hz, 1 H), 3.79 (spt, J = 6.8 Hz, 1 H), 1.38 (d, J =
6.8 Hz, 6 H). LC−MS (m/z): 356.1 [M + H]+.
3-((4-(2-Cyclopropylpyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)benzonitrile (21h). In a vial 7e (100 mg,
368 μmol) and 3-aminobenzonitrile (87 mg, 736 μmol) were stirred
in 1.5 mL of n-BuOH. The reaction mixture was subjected to
microwave irradiation at 150 °C for 2 h. The reaction was filtered and
washed with diethyl ether to give the crude product in the precipitate.
Column purification was performed using MeOH/DCM 0−3%
followed by reverse phase purification using ACN/water 5−95%
with 0.1% formic acid to afford the title compound as a white solid
(46.1 mg, 35%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.68 (dd,
J = 8.8, 2.0 Hz, 1 H), 8.52 (d, J = 5.4 Hz, 1 H), 8.34−8.35 (m, 1 H),
8.33 (dd, J = 4.4, 2.0 Hz, 1 H), 7.65−7.70 (m, 1 H), 7.41−7.45 (m, 3
H), 7.34 (d, J = 7.8 Hz, 1 H), 7.16 (dd, J = 8.8, 4.4 Hz, 1 H), 2.31−
2.39 (m, 1 H), 1.30−1.35 (m, 2 H), 1.15−1.20 (m, 2 H). LC−MS
(m/z): 354.1 [M + H]+.
4-(6-Morpholinopyrazolo[1,5-b]pyridazin-3-yl)-N-phenyl-
pyrimidin-2-amine (22a). In a reaction vial were added 7b (20 mg,
63 μmol) and aniline (12 μL, 126 μmol) in n-BuOH (1 mL), the
reaction mixture was subjected to microwave irradiation at 150 °C for
1 h. Then the reaction mixture was evaporated to dryness and column
purification done using EtOAc/hex 50−100% 12 CV followed by
EtOAc/MeOH 1−20% 5 CV to afford the title compound as a
yellow/brown solid (10 mg, 42%). 1H NMR (500 MHz, chloroform-
d) δ ppm 8.65 (d, J = 9.8 Hz, 1 H), 8.37 (d, J = 5.4 Hz, 1 H), 8.26 (s,
1 H), 7.62 (d, J = 7.8 Hz, 2 H), 7.38 (t, J = 7.8 Hz, 2 H), 7.25 (br s, 1
H), 7.11 (t, J = 7.8 Hz, 1 H), 7.02 (d, J = 5.4 Hz, 1 H), 6.87 (d, J = 9.8
Hz, 1 H), 3.86 (t, J = 4.4 Hz, 4 H), 3.59 (t, J = 4.4 Hz, 4 H). LC−MS
(m/z): 374.0 [M + H]+.
N-(3-Methoxyphenyl)-4-(6-morpholinopyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-amine (22b). In a vial 7b (0.020 g,
63.14 μmol) and m-anisidine (15 μL, 126 μmol) were stirred in n-
BuOH. The reaction mixture was subjected to microwave irradiation
at 150 °C for 1 h. On cooling solid precipitation seen, which was
filtered and washed with diethyl ether and air-dried to afford the title
compound as a dark brown solid (14 mg, 55%). 1H NMR (500 MHz,
chloroform-d) δ ppm 8.70 (d, J = 9.8 Hz, 1 H), 8.38 (d, J = 5.4 Hz, 1
H), 8.27 (s, 1 H), 7.36 (t, J = 2.4 Hz, 1 H), 7.27−7.31 (m, 1 H),
7.10−7.15 (m, 2 H), 7.03 (d, J = 5.4 Hz, 1 H), 6.89 (d, J = 9.8 Hz, 1
H), 6.66 (dd, J = 8.3, 2.4 Hz, 1 H), 3.87 (t, J = 4.9 Hz, 4 H), 3.83 (s, 3
H), 3.60 (t, J = 4.9 Hz, 4 H). LC−MS (m/z): 404.0 [M + H]+.
3-((4-(6-Morpholinopyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)benzonitrile (22c). In a vial 7b (20 mg, 63
μmol), K3PO4 (27 mg, 126 μmol), XPhos (5 mg, 9.5 μmol),
tris(dibenzylideneacetone)palladium(0) (3 mg, 3.2 μmol), and m-
aminobenzonitrile (15 mg, 126 μmol) were added. The vial was
sealed with a stir bar and then evacuated and backfilled with N2 three
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times, 1 mL of n-BuOH was added to a sealed vial. The reaction was
left stirring at 101 °C for 16 h. Solid precipitation was seen in the
reaction vial, which was filtered and washed with diethyl ether.
Column purification was undertaken on the precipitate using EtOAc/
hex 70−100% 5 CV followed by MeOH/EtOAc 1−20% 10 CV to
afford the title compound as a white solid (6.3 mg, 25%). 1H NMR
(500 MHz, chloroform-d) δ ppm 8.68 (d, J = 9.8 Hz, 1 H), 8.39−8.45
(m, 2 H), 8.28 (s, 1 H), 7.56 (ddd, J = 7.8, 2.4, 1.0 Hz, 1 H), 7.45 (t, J
= 7.8 Hz, 1 H), 7.36 (dt, J = 7.8, 1.0 Hz, 1 H), 7.32 (br s, 1 H), 7.12
(d, J = 5.4 Hz, 1 H), 7.06 (d, J = 9.8 Hz, 1 H), 3.87 (t, J = 4.9 Hz, 4
H), 3.61 (t, J = 4.9 Hz, 4 H). LC−MS (m/z): 399.0 [M + H]+.
3-((4-(6-Methoxypyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
yl)amino)benzonitrile (22d). In a vial 3- 7c (15 mg, 57 μmol) and
3-aminobenzonitrile (34 mg, 287 μmol) were stirred in n-BuOH (1.5
mL) and subjected to microwave irradiation at 150 °C for 2 h. The
reaction mixture was then heated to 110 °C using conventional
heating for an additional 96 h. The mixture was then concentrated,
and column purification was undertaken using EtOAc/hex, 25−33%
to yield the title compound as a white solid (7.0 mg, 37%). 1H NMR
(500 MHz, chloroform-d) δ ppm 8.74 (d, J = 9.8 Hz, 1 H), 8.45 (d, J
= 5.4 Hz, 1 H), 8.32−8.36 (m, 2 H), 7.62−7.67 (m, 1 H), 7.45 (t, J =
7.8 Hz, 1 H), 7.36 (d, J = 7.8 Hz, 1 H), 7.20 (br s, 1 H), 7.14 (d, J =
5.4 Hz, 1 H), 6.95 (d, J = 9.8 Hz, 1 H), 4.11 (s, 3 H). LC−MS (m/z):
344.1 [M + H]+.
3-((4-(2-(Hydroxymethyl)-6-methoxypyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-yl)amino)benzonitrile (23a). In a
vial 7l (20 mg, 69 μmol) and 3-aminobenzonitrile (24 mg, 206 μmol)
were added to n-BuOH (1 mL), and the reaction was heated to 150
°C for 2 h, then 180 °C for 3 h. The reaction was filtered and washed
with diethyl ether to yield the desired product in the precipitate as a
white solid (7.2 mg, 28%). 1H NMR (400 MHz, DMSO-d6) δ ppm
9.96 (s, 1 H), 8.93 (d, J = 9.5 Hz, 1 H), 8.59 (d, J = 5.1 Hz, 1 H), 8.38
(t, J = 1.5 Hz, 1 H), 7.93−7.98 (m, 1 H), 7.47−7.56 (m, 2 H), 7.41
(dt, J = 7.3, 1.5 Hz, 1 H), 7.14 (d, J = 9.5 Hz, 1 H), 5.59 (t, J = 5.1 Hz,
1 H), 4.80 (d, J = 5.1 Hz, 2 H), 4.00 (s, 3 H). LC−MS (m/z): 374.1
[M + H]+.
3-((4-(2-(Hydroxymethyl)-6-morpholinopyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-yl)amino)benzonitrile (23b). In a
vial 7m (30 mg, 87 μmol) and 3-aminobenzonitrile (20 mg, 173
μmol) were stirred in 1.5 mL of n-BuOH, and the reaction was
subjected to microwave irradiation at 150 °C for 3 h. The reaction
was filtered and washed with diethyl ether to give the crude product in
the precipitate. Column purification was undertaken using MeOH/
DCM 2−30% to afford the title compound as a white solid (20.8 mg,
56%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.94 (s, 1 H), 8.76 (d,
J = 9.8 Hz, 1 H), 8.56 (d, J = 5.4 Hz, 1 H), 8.36 (s, 1 H), 7.95−7.99
(m, 1 H), 7.53 (t, J = 8.3 Hz, 1 H), 7.46 (d, J = 5.4 Hz, 1 H), 7.36−
7.42 (m, 2 H), 5.52 (t, J = 4.9 Hz, 1 H), 4.76 (d, J = 4.9 Hz, 2 H),
3.76 (t, J = 4.9 Hz, 4 H), 3.52 (t, J = 4.9 Hz, 4 H). LC−MS (m/z):
429.1 [M + H]+.
3-((4-(2-Cyclopropyl-6-morpholinopyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-yl)amino)benzonitrile (23c). In a
vial 7o (25 mg, 70 μmol), cesium carbonate (69 mg, 220 μmol), 3-
aminopyridine (17 mg, 140 μmol), palladium(II) acetate (0.8 mg, 3.5
μmol), and Xantphos (4.1 mg, 7.0 μmol) were stirred in anhydrous
dioxane (2 mL), the reaction mixture was sealed then evacuated and
backfilled with N2 three times. The reaction mixture was then
subjected to microwave irradiation at 160 °C for 1 h. The reaction
was filtered through Celite and washed with EtOAc, then evaporated
to dryness. Column purification was performed using EtOAc/hex 25−
75%, to afford the title compound as an orange solid (21.5 mg, 70%).
1H NMR (500 MHz, chloroform-d) δ ppm 8.51 (d, J = 9.8 Hz, 1 H),
8.46 (d, J = 5.4 Hz, 1 H), 8.39 (s, 1 H), 7.62 (dd, J = 8.3, 2.0 Hz, 1
H), 7.40−7.49 (m, 2 H), 7.34 (d, J = 7.8 Hz, 1 H), 7.22−7.25 (s, 1
H), 6.95 (d, J = 9.8 Hz, 1 H), 3.85 (t, J = 4.4 Hz, 4 H), 3.57 (t, J = 5.4
Hz, 4 H), 2.22−2.29 (m, 1 H), 1.23−1.28 (m, 2 H), 1.08−1.14 (m, 2
H) LC−MS (m/z): 439.1 [M + H]+.
4-(2-Cyclopropylpyrazolo[1,5-b]pyridazin-3-yl)-N-(pyridin-
3-yl)pyrimidin-2-amine (23d). In a vial 3-(2-chloropyrimidin-4-yl)-
2-cyclopropylpyrazolo[1,5-b]pyridazine 7e (30 mg, 110 μmol),
cesium carbonate (108 mg, 331 μmol), 3-aminopyridine (21 mg,
220 μmol), palladium(II) acetate (1.2 mg, 5.5 μmol), and Xantphos
(6.4 mg, 11 μmol) were stirred in anhydrous dioxane (1.5 mL), the
reaction mixture was sealed then evacuated and backfilled with N2
three times. The reaction mixture was then subjected to microwave
irradiation at 160 °C for 1 h. The reaction was filtered through Celite
and washed with EtOAc, then evaporated to dryness. Reverse phase
column purification was done using ACN/water 5−95% with 0.1%
formic acid, to afford the title compound as a white solid (17.0 mg,
47%). 1H NMR (500 MHz, methanol-d4) δ ppm 8.92 (d, J = 2.4 Hz,
1 H), 8.89 (dd, J = 8.8, 2.0 Hz, 1 H), 8.52 (d, J = 5.4 Hz, 1 H), 8.40
(dd, J = 4.4, 2.0 Hz, 1 H), 8.32 (ddd, J = 8.3, 2.4, 1.5 Hz, 1 H), 8.17
(dd, J = 4.6, 1.5 Hz, 1 H), 7.47 (d, J = 5.4 Hz, 1 H), 7.39 (dd, J = 8.3,
4.6 Hz, 1 H), 7.28 (dd, J = 8.8, 4.4 Hz, 1 H), 2.45−2.53 (m, 1 H),
1.11−1.23 (m, 4 H). LC−MS (m/z): 330.1 [M + H]+.
4-(6-Methoxypyrazolo[1,5-b]pyridazin-3-yl)-N-(pyridin-3-
yl)pyrimidin-2-amine (23e). In a vial 7c (30 mg, 115 μmol),
cesium carbonate (112 mg, 344 μmol), 3-aminopyridine (22 mg, 230
μmol), palladium(II) acetate (1.3 mg, 5.7 μmol), and Xantphos (6.6
mg, 12 μmol) were stirred in anhydrous dioxane (1.5 mL). The
reaction mixture was sealed then evacuated and backfilled with N2
three times. The reaction mixture was then subjected to microwave
irradiation at 160 °C for 1 h. The reaction was filtered through Celite
and washed with MeOH, then evaporated to dryness. Reverse phase
column purification was performed ACN/water 5−95% with 0.1%
formic acid, affording the title compound as a yellow solid (10.3 mg,
28%). 1H NMR (500 MHz, DMSO-d6) δ ppm 9.75 (s, 1 H), 9.00 (d,
J = 9.8 Hz, 1 H), 8.88 (d, J = 2.9 Hz, 1 H), 8.71 (s, 1 H), 8.49 (d, J =
5.4 Hz, 1 H), 8.23 (ddd, J = 8.3, 2.9, 1.5 Hz, 1 H), 8.19 (dd, J = 4.9,
1.5 Hz, 1 H), 7.39 (d, J = 5.4 Hz, 1 H), 7.36 (dd, J = 8.3, 4.9 Hz, 1
H), 7.18 (d, J = 9.8 Hz, 1 H), 4.02 (s, 3 H). LC−MS (m/z): 320.1
[M + H]+.
(6-Methoxy-3-(2-(pyridin-3-ylamino)pyrimidin-4-yl)-
pyrazolo[1,5-b]pyridazin-2-yl)methanol (23f). In a vial 7l (30
mg, 103 μmol), cesium carbonate (101 mg, 309 μmol), 3-
aminopyridine (19.4 mg, 206 μmol), palladium(II) acetate (1.2 mg,
8.2 μmol), and Xantphos (6.0 mg, 10.3 μmol) were stirred in
anhydrous dioxane (1.5 mL). The reaction mixture was sealed then
evacuated and backfilled with nitrogen 3×. The reaction mixture was
then subjected to MW irradiation at 160 °C for 1.5 h. The reaction
was filtered through Celite and washed with MeOH, then evaporated
to dryness. Reverse phase column purification was performed ACN/
water 5−95% with 0.1% formic acid, to afford the title compound as a
yellow solid (15.5 mg, 43%). 1H NMR (500 MHz, DMSO-d6) δ ppm
9.75 (s, 1 H), 8.92 (d, J = 9.8 Hz, 1 H), 8.88 (d, J = 2.4 Hz, 1 H), 8.54
(d, J = 5.4 Hz, 1 H), 8.24 (ddd, J = 8.3, 2.4, 1.5 Hz, 1 H), 8.18 (dd, J
= 4.4, 1.5 Hz, 1 H), 7.45 (d, J = 5.4 Hz, 1 H), 7.34 (dd, J = 8.3, 4.4
Hz, 1 H), 7.13 (d, J = 9.8 Hz, 1 H), 5.53−5.58 (m, 1 H), 4.80 (d, J =
2.4 Hz, 2 H), 4.00 (s, 3 H). LC−MS (m/z): 350.2 [M + H]+.
4-(2-Cyclopropyl-6-methoxypyrazolo[1,5-b]pyridazin-3-yl)-
N-(pyridin-3-yl)pyrimidin-2-amine (23g). In a vial 7n (30 mg, 99
μmol), cesium carbonate (97 mg, 298 μmol), 3-aminopyridine (19
mg, 199 μmol), palladium(II) acetate (1.1 mg, 5.0 μmol), and
Xantphos (5.8 mg, 10.0 μmol) were stirred in anhydrous dioxane (1.5
mL). The reaction mixture was sealed then evacuated and backfilled
with N2 three times. The reaction mixture was then subjected to
microwave irradiation at 160 °C for 1 h. The reaction was filtered
through Celite and washed with MeOH, then evaporated to dryness.
Reverse phase preparative HPLC purification was performed using
ACN/water 5−95% with 0.1% formic acid, to provide the title
compound as a yellow solid (7.4 mg, 21%). 1H NMR (500 MHz,
methanol-d4) δ ppm 8.90 (d, J = 2.9 Hz, 1 H), 8.77 (d, J = 9.3 Hz, 1
H), 8.49 (d, J = 5.4 Hz, 1 H), 8.31 (ddd, J = 8.3, 2.9, 1.5 Hz, 1 H),
8.17 (dd, J = 4.9, 1.5 Hz, 1 H), 7.45 (d, J = 5.4 Hz, 1 H), 7.39 (dd, J =
8.3, 4.9 Hz, 1 H), 6.94 (d, J = 9.3 Hz, 1 H), 4.04 (s, 3 H), 2.36−2.43
(m, 1 H), 1.11−1.17 (m, 2 H), 1.05−1.10 (m, 2 H). LC−MS (m/z):
360.2 [M + H]+.
4-(2-Cyclopropyl-6-morpholinopyrazolo[1,5-b]pyridazin-3-
yl)-N-(pyridin-3-yl)pyrimidin-2-amine (23h). In a vial 7o (30 mg,
84 μmol), cesium carbonate (82 mg, 252 μmol), 3-aminopyridine (16
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mg, 168 μmol), palladium(II) acetate (0.9 mg, 4.2 μmol), and
Xantphos (5 mg, 8.4 μmol) were stirred in anhydrous dioxane (1.5
mL), and the reaction mixture was sealed then evacuated and
backfilled with N2 three times. The reaction mixture was then
subjected to microwave irradiation at 160 °C for 1 h. The reaction
was filtered through Celite and washed with EtOAc, then evaporated
to dryness. Reverse phase preparative HPLC purification was
performed using ACN/water 5−95% with 0.1% formic acid, to afford
the title compound as a pale-yellow solid (11.0 mg, 32%). 1H NMR
(500 MHz, methanol-d4) δ ppm 8.91 (d, J = 2.9 Hz, 1 H), 8.62 (d, J =
9.8 Hz, 1 H), 8.46 (d, J = 5.4 Hz, 1 H), 8.29 (ddd, J = 8.3, 2.9, 1.5 Hz,
1 H), 8.16 (dd, J = 4.9, 1.5 Hz, 1 H), 7.43 (d, J = 5.4 Hz, 2 H), 7.40
(dd, J = 8.3, 4.9 Hz, 1 H), 7.17 (d, J = 9.8 Hz, 1 H), 3.83 (t, J = 4.9
Hz, 4 H), 3.55 (t, J = 4.9 Hz, 4 H), 2.32−2.42 (m, 1 H), 1.10−1.15
(m, 2 H), 1.04−1.08 (m, 2 H). LC−MS (m/z): 415.1 [M + H]+.
4-(6-Morpholinopyrazolo[1,5-b]pyridazin-3-yl)-N-(pyridin-
3-yl)pyrimidin-2-amine (23i). In a vial 7b (30 mg, 95 μmol),
cesium carbonate (93 mg, 284 μmol), 3-aminopyridine (18 mg, 189
μmol), palladium(II) acetate (1.1 mg, 4.7 μmol), and Xantphos (5.5
mg, 9.5 μmol) were stirred in anhydrous dioxane (1.5 mL), and the
reaction mixture was sealed then evacuated and backfilled with N2
three times. The reaction mixture was then subjected to microwave
irradiation at 160 °C for 1 h. The reaction was filtered through Celite
and washed with EtOAc, then evaporated to dryness. Reverse phase
preparative HPLC purification was performed using ACN/water 5−
95% with 0.1% formic acid, affording the title compound as a white
solid (7.2 mg, 20%). 1H NMR (500 MHz, methanol-d4) δ ppm 8.89−
8.93 (m, 1 H), 8.79 (d, J = 9.8 Hz, 1 H), 8.38−8.42 (m, 2 H), 8.26
(ddd, J = 8.3, 2.9, 1.5 Hz, 1 H), 8.15−8.21 (m, 1 H), 7.40 (dd, J = 8.3,
4.9 Hz, 1 H), 7.24−7.29 (m, 2 H), 3.85 (t, J = 4.9 Hz, 4 H), 3.60 (t, J
= 4.9 Hz, 4 H). LC−MS (m/z): 375.1 [M + H]+.
4-((4-(6-Morpholinopyrazolo[1,5-b]pyridazin-3-yl)-
pyrimidin-2-yl)amino)cyclohexan-1-ol (23j). In a vial 2−4b (20
mg, 63 μmol), and trans-4-amino-cyclohexanol (36 mg, 316 μmol)
were stirred in n-BuOH (2 mL) and heated to 110 °C for 72 h.
Reaction mixture was then concentrated and column purification was
undertaken using MeOH/DCM, 2−5% to afford the title compound
as a white solid (16.3 mg, 65.3%). 1H NMR (500 MHz, methanol-d4)
δ ppm 8.82 (d, J = 9.8 Hz, 1 H), 8.37 (s, 1 H), 8.18 (d, J = 5.4 Hz, 1
H), 7.30 (d, J = 9.8 Hz, 1 H), 6.99 (d, J = 5.4 Hz, 1 H), 3.80−3.90
(m, 5 H), 3.56−3.68 (m, 5 H), 2.12−2.20 (m, 2 H), 2.01−2.09 (m, 2
H), 1.38−1.55 (m, 4 H). LC−MS (m/z): 396.2 [M + H]+.
4-((4-(6-Methoxypyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-
yl)amino)cyclohexan-1-ol (23k). In a vial 7c (50 mg, 191 μmol)
and trans-4-aminocyclohexanol (44 mg, 392 μmol) were stirred in n-
BuOH (1.5 mL) and subjected to microwave irradiation at 150 °C for
2.5 h. The reaction was concentrated in vacuo then subjected to
column purification MeOH/DCM 0−5%, to afford the title
compound as a yellow solid (38.5 mg, 59%). 1H NMR (500 MHz,
methanol-d4) δ ppm 8.88−8.95 (m, 1 H), 8.42 (s, 1 H), 8.18 (d, J =
5.4 Hz, 1 H), 6.98−7.03 (m, 2 H), 4.07 (s, 3 H), 3.75−3.84 (m, 1 H),
3.58−3.66 (m, 1 H), 2.08−2.17 (m, 2 H), 1.99−2.06 (m, 2 H), 1.35−
1.52 (m, 4 H). LC−MS (m/z): 341.2 [M + H]+.
4-((4-(2-Cyclopropyl-6-methoxypyrazolo[1,5-b]pyridazin-3-
yl)pyrimidin-2-yl)amino)cyclohexan-1-ol (23l). In a vial 7n (30
mg, 99 μmol) and trans-4-aminocyclohexanol (23 mg, 199 μmol)
were stirred in n-BuOH (1.5 mL) subjected to microwave irradiation
at 150 °C for 2 h. The reaction was concentrated in vacuo then
subjected to column purification MeOH/DCM 0−10%, to afford the
title compound as a white solid (17.3 mg, 66% based on recovered
starting material). 1H NMR (500 MHz, methanol-d4) δ ppm 8.69−
8.76 (m, 1 H), 8.23 (d, J = 5.4 Hz, 1 H), 7.16 (d, J = 5.4 Hz, 1 H),
6.92 (d, J = 9.3 Hz, 1 H), 4.03 (s, 3 H), 3.75−3.85 (m, 1 H), 3.57−
3.65 (m, 1 H), 2.33−2.41 (m, 1 H), 2.07−2.16 (m, 2 H), 1.99−2.05
(m, 2 H), 1.36−1.48 (m, 4 H), 1.09−1.13 (m, 2 H), 1.04−1.07 (m, 2
H). LC−MS (m/z): 381.2 [M + H]+.
4-((4-(2-(Hydroxymethyl)-6-methoxypyrazolo[1,5-b]-
pyridazin-3-yl)pyrimidin-2-yl)amino)cyclohexan-1-ol (23m).
In a vial 7l (50 mg, 171 μmol) and trans-4-aminocyclohexanol
(39.5 mg, 343 μmol) were stirred in n-BuOH (1.5 mL) and subjected
to microwave irradiation at 150 °C for 2 h. The reaction was
concentrated in vacuo then subjected to column purification EtOAc/
hex 25−100%, to afford the title compound as a yellow solid (33.2
mg, 52%). 1H NMR (500 MHz, methanol-d4) δ ppm 8.70 (d, J = 9.8
Hz, 1 H), 8.26 (d, J = 5.4 Hz, 1 H), 7.09 (d, J = 5.4 Hz, 1 H), 7.00 (d,
J = 9.8 Hz, 1 H), 4.91 (s, 2 H), 4.06 (s, 3 H), 3.75−3.83 (m, 1 H),
3.57−3.65 (m, 1 H), 2.07−2.15 (m, 2 H), 2.00−2.03 (m, 2 H), 1.35−
1.50 (m, 4 H). LC−MS (m/z): 371.2 [M + H]+.
2-Chloro-4-methyl-6-((trimethylsilyl)ethynyl)pyrimidine
(24a). In a reaction vial 2,4-dichloro-6-methylpyrimidine (1 g, 6.1
mmol), Pd(PPh3)2Cl2 (86 mg, 123 μmol), and CuI (35 mg, 184
μmol) were added. A degassed solution of triethylamine (2.6 mL, 18.4
mmol) and THF (12 mL) were added under N2 to the reaction vial,
followed by ethynyltrimethylsilane (961 μL, 6.75 mmol). The
reaction mixture was heated to 50 °C for 16 h. Reaction mixture
was then filtered through Celite and washed with EtOAc. The
reaction mixture was concentrated in vacuo then subjected to column
purification EtOAc/hexanes 0−10%, to yield the desired product as
an off-white solid (370 mg, 27%). 1H NMR (500 MHz, chloroform-d)
δ ppm 7.16 (s, 1 H), 2.48 (s, 3 H), 0.24 (s, 9 H). LC−MS (m/z):
225.0 (35Cl), 227.0 (37Cl) [M + H]+.
2-Chloro-4-ethynyl-6-methylpyrimidine (24b). In a vial 24a
(370 mg, 1.65 mmol) was stirred in MeOH (10 mL), and KOH (0.46
mg, 8.2 μmol) was added. After 30 min the reaction was stopped and
concentrated in vacuo, to yield the product as a pale-yellow solid (240
mg, 96%). 1H NMR (500 MHz, chloroform-d) δ ppm 7.23 (s, 1 H),
3.40 (s, 1 H), 2.55 (s, 3 H). LC−MS (m/z): 152.7 (35Cl), 154.7
(37Cl) [M + H]+.
3-(2-Chloro-6-methylpyrimidin-4-yl)pyrazolo[1,5-b]-
pyridazine (25). (Aminooxy)sulfonic acid (889 mg, 7.86 mmol) was
dissolved in 7 mL of water, and to the clear solution was added
saturated sodium bicarbonate until effervescence ceased (pH ∼ 6).
The clear colorless solution was heated to 70 °C, and pyridazine (378
μL, 5.24 mmol) was added and the reaction mixture was stirred at 70
°C for 2 h. The reaction was cooled to room temperature, neutralized
with saturated sodium bicarbonate (until effervescence ceased) and
then solution of 24b (200 mg, 1.31 mmol) in DCM (20 mL) was
added followed by KOH (74 mg, 1.3 mmol) and the reaction was
stirred at room temperature for 16 h. The reaction mixture was
diluted with DCM and washed with water and brine then dried over
sodium sulfate, filtered and evaporated to get the crude product which
was purified by column chromatography using EtOAc/hex 30−50%
to provide the desired compound as a pink solid (121 mg, 38%). 1H
NMR (500 MHz, chloroform-d) δ ppm 9.06 (dd, J = 9.3, 2.0 Hz, 1
H), 8.53 (s, 1 H), 8.46 (dd, J = 4.4, 2.0 Hz, 1 H), 7.40 (s, 1 H), 7.29
(dd, J = 9.3, 4.4 Hz, 1 H), 2.59 (s, 3 H). LC−MS (m/z): 246.1 (35Cl),
248.0 (37Cl) [M + H]+.
2-Chloro-5-methyl-4-((trimethylsilyl)ethynyl)pyrimidine
(26a). In a reaction vial 2,4-dichloro-5-methylpyrimidine (1 g, 6.1
mmol), Pd(PPh3)2Cl2 (86 mg, 123 μmol), and CuI (35 mg, 184
μmol) were added. A degassed solution of triethylamine (2.6 mL, 18.4
mmol) in THF (12 mL) was added under N2 to the reaction vial,
followed by ethynyltrimethylsilane (961 μL, 6.75 mmol). The
reaction mixture was heated to 50 °C for 16 h. The reaction was
then filtered through Celite and washed with EtOAc. The reaction
mixture was concentrated in vacuo and subjected to column
purification EtOAc/hexanes 0−10%, to provide the compound as a
white solid (713 mg, 52%). 1H NMR (500 MHz, chloroform-d) δ
ppm 8.46 (s, 1 H), 2.36 (s, 3 H), 0.28 (s, 9 H). LC−MS (m/z): 225.0
(35Cl), 227.0 (37Cl) [M + H]+.
2-Chloro-4-ethynyl-5-methylpyrimidine (26b). In a vial 26a
(713 mg, 3.2 mmol) was stirred in MeOH (20 mL), and KOH (0.9
mg, 16 μmol) was added, and the reaction was stirred at room
temperature. After 30 min the reaction was stopped and concentrated
in vacuo, then subjected to column purification EtOAc/hex 10−25%
to obtain the desired compound as a white solid (361 mg, 75%). 1H
NMR (500 MHz, DMSO-d6) δ ppm 8.74 (s, 1 H), 5.13 (s, 1 H), 2.31
(s, 3 H). LC−MS (m/z): 152.8 (35Cl), 154.7 (37Cl) [M + H]+.
3-(2-Chloro-5-methylpyrimidin-4-yl)pyrazolo[1,5-b]-
pyridazine (27). (Aminooxy)sulfonic acid (889 mg, 7.86 mmol) was
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dissolved in 7 mL of water, and saturated sodium bicarbonate was
added to the clear solution until effervescence ceased (pH ∼ 6). The
clear colorless solution was heated at 70 °C, and pyridazine (378 μL,
5.24 mmol) was added and the reaction mixture was stirred at 70 °C
for 2 h. The reaction was then cooled to room temperature,
neutralized with saturated sodium bicarbonate (until effervescence
ceased) and then a solution of 26b (200 mg, 1.31 mmol) in DCM (20
mL) was added followed by KOH (148 mg, 2.6 mmol) and the
reaction was stirred at room temperature for 16 h. The reaction
mixture was diluted with DCM and washed with water and brine then
dried over sodium sulfate, filtered and evaporated to get the crude
product which was purified by column chromatography using
MeOH/DCM 0−2% to yield the desired compound as a brown
solid (206 mg, 64%). 1H NMR (500 MHz, chloroform-d) δ ppm 9.13
(dd, J = 9.3, 2.0 Hz, 1 H), 8.55 (s, 1 H), 8.50 (dd, J = 4.4, 2.0 Hz, 1
H), 8.45 (s, 1 H), 7.32 (dd, J = 9.3, 4.4 Hz, 1 H), 2.60 (s, 3 H). LC−
MS (m/z): 246.1 (35Cl), 248.0 (37Cl) [M+1].
2-(3-Chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lane (28). In a vial 3-chloroiodobenzene (52 μL, 420 μmol),
bis(pinacolato)diboron (160 mg, 629 μmol), potassium acetate (144
mg, 1.47 mmol), and PdCl2(dppf)·CH2Cl2 (17 mg, 21 mmol) were
combined, and the vial was sealed. Anhydrous dioxane (3 mL) was
added and the reaction was evacuated and backfilled with N2 three
times, then subjected to microwave irradiation at 160 °C for 30 min.
The reaction was cooled and filtered through Celite, concentrated in
vacuo and taken forward without purification. LC−MS (m/z): 156.7
(35Cl), 158.8 (37Cl) [M + H]+ (boronic acid).
3-(6-Chloropyridin-2-yl)pyrazolo[1,5-b]pyridazine (29).
(Aminooxy)sulfonic acid (296 mg, 2.62 mmol) was dissolved in 2
mL of water, and to the clear solution was added saturated sodium
bicarbonate until effervescence ceased (pH ∼ 6). The clear colorless
solution was heated to 70 °C, then pyridazine (126 μL, 1.74 mmol)
was added, and the reaction mixture was stirred at 70 °C for 2 h. The
reaction mixture was then cooled to room temperature, neutralized
with saturated sodium bicarbonate (until effervescence ceased) and
then solution of 2-chloro-6-ethynylpyridine (120 mg, 872 μmol) in
DCM (10 mL) was added followed by KOH (49 mg, 872 μmol) and
the reaction mixture was stirred at 40 °C for 72 h, partial conversion
to product was observed. Additional KOH (49 mg, 872 μmol) was
added and the reaction was stirred for another 24 h at 40 °C. The
reaction mixture was diluted with DCM and water and extracted. The
organic layer was washed with brine then dried over sodium sulfate,
filtered and evaporated to get the crude product which was purified by
column chromatography using EtOAc/hex 25% to yield the product
as a tan solid (18.5 mg, 15% based on recovered starting material). 1H
NMR (400 MHz, chloroform-d) δ ppm 9.00 (dd, J = 8.8, 2.2 Hz, 1
H), 8.44 (s, 1 H), 8.38 (dd, J = 4.4, 2.2 Hz, 1 H), 7.69 (t, J = 8.1 Hz, 1
H), 7.58 (d, J = 8.1 Hz, 1 H), 7.13−7.22 (m, 2 H). LC−MS (m/z):
231.0 (35Cl), 233.0 (37Cl) [M + H]+.
3-(2-Chloropyridin-4-yl)pyrazolo[1,5-b]pyridazine (30).
(Aminooxy)sulfonic acid (2.06 g, 18.2 mmol) was dissolved in 4
mL of water, and saturated sodium bicarbonate was added to the clear
solution until effervescence ceased (pH ∼ 6). The clear colorless
solution was heated at 70 °C, and pyridazine (875 μL, 12.1 mmol)
was added. The reaction mixture heated at 70 °C for 2 h, then cooled
to room temperature, neutralized with saturated sodium bicarbonate
(until effervescence ceased) and then a solution of 2-chloro-4-
ethynylpyridine (417 mg, 3.03 mmol) in DCM (15 mL) and KOH
(170 mg, 3.0 mmol) was added then reaction mixture was stirred for
16 h at room temperature. The reaction mixture was diluted with
DCM and washed with water and brine then dried over magnesium
sulfate, filtered and evaporated to get the crude product which was
purified by column chromatography using MeOH/DCM 0−2%
followed by an additional column purification using EtOAc/hexanes
25−100% to afford the desired compound as a brown solid (173 mg,
25%). 1H NMR (500 MHz, chloroform-d) δ ppm 8.46 (d, J = 5.4 Hz,
1 H), 8.43 (dd, J = 4.4, 2.0 Hz, 1 H), 8.36 (s, 1 H), 8.28 (dd, J = 9.3,
2.0 Hz, 1 H), 7.53−7.56 (m, 1 H), 7.44 (dd, J = 5.4, 1.5 Hz, 1 H),
7.22 (dd, J = 9.3, 4.4 Hz, 1 H). LC−MS (m/z): 230.9 (35Cl), 233.0
(37Cl) [M + H]+.
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Industria y Competitividad (M.N., Grant SAF2015-71444-P;
D.G.P., Grant SAF2016-79957-R., and Subdireccioń General
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